guselkumab vs risankizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-23 p19 · full Psoriasis pipeline

guselkumab · Tremfya

Marketed by Johnson & Johnson

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT02203032 · Phase 3 · completed

In patients who had not responded well enough to ustekinumab, switching to guselkumab under randomized, blinded conditions produced significantly more visits with clear or almost-clear skin than staying on ustekinumab, a clinically meaningful and statistically significant result in a study designed and blinded to make that comparison fairly.

Next expected readout: December 2026 · NCT05004727 (registry estimate)

Reported efficacy

Number of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) From Week 28 Through Week 40: Primary endpoint (NAVIGATE trial), mean number of visits Week 28-40 with IGA 0/1 and >=2-grade improvement: guselkumab 1.5 (SD 1.57, n=135) vs continued ustekinumab 0.7 (SD 1.26, n=133); row mean score test P<0.001. (met)

Result source: NCT02203032

risankizumab · Skyrizi

Marketed by AbbVie and partners

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT02684370 · Phase 3 · completed

This randomized, triple-blind, placebo- and active-controlled trial used validated skin-clearance measures as its primary endpoints, and risankizumab achieved a highly statistically significant improvement over placebo on both: 75.3% vs 4.9% achieving PASI90, and 87.8% vs 7.8% achieving clear-or-almost-clear skin at Week 16.

Next expected readout: April 2028 · NCT04862286 (registry estimate)

Reported efficacy

Percentage of Participants Achieving 90% Improvement Psoriasis Area and Severity Index (PASI) Score (PASI90) From Baseline to Week 16 (Baseline, Week 16); Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16; Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52: Co-primary endpoints at Week 16 (IMMhance study): PASI 90 73% risankizumab vs 2% placebo; sPGA 0/1 84% risankizumab vs 7% placebo; both p<0.001 (met)

Result source: NCT02672852

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointguselkumabrisankizumab
PASI 7584.1% vs 6.3%+77.8 vs placebo100 mg · wk 16 · n 63NCT02325219
11 other results
  • 89.2% vs 6.3% 50 mg · wk 16 · n 65 · Phase 3 · secondary NCT02325219
  • 86.3% vs 68.5% 100 mg · wk 16 · n 496 · Phase 3 · secondary NCT02207244
  • 92.7% vs 92.8% 100 mg · wk 16 · n 534 · Phase 3 · secondary NCT03090100
  • 89.3% vs 91.6% 100 mg · wk 12 · n 534 · Phase 3 · secondary NCT03090100
  • 91.2% vs 73.1% wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • 78.6% vs 4.8% 100 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 81% vs 4.8% 50 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 81% vs 4.8% 200 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 75.6% vs 4.8% 15 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • 43.9% vs 4.8% 5 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • 5.1% vs 22.9% wk 2 · n 507 · Phase 4 · secondary NCT03573323
85.2% vs 85.7%vs Ustekinumabwk 16 · n 54NCT04435600
19 other results
  • 83.3% vs 85.7% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 92.3% vs 85.7% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 86.7% vs 85.7% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 88.7% vs 8% wk 16 · n 407 · Phase 3 · secondary NCT02672852
  • 90.8% vs 6.1% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 90.7% vs 71.7% wk 16 · n 301 · Phase 3 · secondary NCT02694523
  • 86.8% vs 70% wk 12 · n 304 · Phase 3 · secondary NCT02684370
  • 88.8% vs 69.7% wk 12 · n 294 · Phase 3 · secondary NCT02684357
  • 93.3% vs 26.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 86.7% vs 20% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 75% vs 8.3% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 13.3% vs 3.3% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 94.5% vs 8.6% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 89.7% vs 8.6% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 90.5% vs 77.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 97.6% vs 77.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 67.4% vs 77.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 84.7% vs 18.8% wk 16 · n 118 · Phase 4 · secondary NCT04908475
  • 94% vs 77.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481
PASI 9070% vs 2.4%+67.6 vs placebo100 mg · wk 16 · n 496NCT02207244
10 other results
  • 73.3% vs 2.9% wk 16 · n 329 · Phase 3 · primary NCT02207231
  • 69.8% vs 0% 100 mg · wk 16 · n 63 · Phase 3 · primary NCT02325219
  • 70.8% vs 0% 50 mg · wk 16 · n 65 · Phase 3 · primary NCT02325219
  • 75.8% vs 0% wk 16 · n 62 · Phase 3 · primary NCT02905331
  • 70% vs 46.8% 100 mg · wk 16 · n 496 · Phase 3 · secondary NCT02207244
  • 78.5% vs 79.6% 100 mg · wk 16 · n 534 · Phase 3 · secondary NCT03090100
  • 69.1% vs 76.1% 100 mg · wk 12 · n 534 · Phase 3 · secondary NCT03090100
  • 73.3% vs 49.7% wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • 35.9% vs 58.5% wk 8 · n 507 · Phase 4 · secondary NCT03573323
  • 7.9% vs 21% wk 4 · n 507 · Phase 4 · secondary NCT03573323
75.3% vs 4.9%+70.4 vs placebowk 16 · n 304NCT02684370
22 other results
  • 73.2% vs 2% wk 16 · n 407 · Phase 3 · primary NCT02672852
  • 74.8% vs 2% wk 16 · n 294 · Phase 3 · primary NCT02684357
  • 62.9% vs 3.8% wk 16 · n 105 · Phase 3 · primary NCT03875482
  • 72.4% vs 47.4% wk 16 · n 301 · Phase 3 · primary NCT02694523
  • 73.8% vs 65.6% wk 16 · n 164 · Phase 3 · primary NCT03478787
  • 75.3% vs 42% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 74.8% vs 47.5% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 64.8% vs 60.7% wk 16 · n 54 · Phase 3 · secondary NCT04435600
  • 76.7% vs 11.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 61.7% vs 5% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 38.3% vs 1.7% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 1.7% vs 0% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 83.3% vs 60.7% wk 16 · n 12 · Phase 3 · secondary NCT04435600
  • 84.6% vs 60.7% wk 16 · n 13 · Phase 3 · secondary NCT04435600
  • 76.7% vs 60.7% wk 16 · n 30 · Phase 3 · secondary NCT04435600
  • 74.5% vs 1.7% 150 mg · wk 16 · n 55 · Phase 2 · primary NCT03000075
  • 75.9% vs 1.7% 75 mg · wk 16 · n 58 · Phase 2 · primary NCT03000075
  • 81% vs 40% 180 mg · wk 12 · n 42 · Phase 2 · primary NCT02054481
  • 73.2% vs 40% 90 mg · wk 12 · n 41 · Phase 2 · primary NCT02054481
  • 32.6% vs 40% 18 mg · wk 12 · n 43 · Phase 2 · primary NCT02054481
  • 55.9% vs 5.1% wk 16 · n 118 · Phase 4 · primary NCT04908475
  • 77.1% vs 40% 90+180 mg · wk 12 · n 83 · Phase 2 · primary NCT02054481
PASI 10050% vs 0%+50 vs placebowk 16 · n 62NCT02905331
3 other results
  • 24.9% vs 41.3% wk 12 · n 507 · Phase 4 · primary NCT03573323
  • 13.6% vs 29.6% wk 8 · n 507 · Phase 4 · secondary NCT03573323
  • 1.4% vs 6.7% wk 4 · n 507 · Phase 4 · secondary NCT03573323
35.9% vs 0%+35.9 vs placebowk 16 · n 304NCT02684370
20 other results
  • 47.2% vs 1% wk 16 · n 407 · Phase 3 · secondary NCT02672852
  • 50.7% vs 2% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 38.1% vs 1.9% wk 16 · n 105 · Phase 3 · secondary NCT03875482
  • 35.9% vs 12% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 50.7% vs 24.2% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 39.9% vs 23% wk 16 · n 301 · Phase 3 · secondary NCT02694523
  • 40.7% vs 17.9% wk 16 · n 54 · Phase 3 · secondary NCT04435600
  • 35% vs 1.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 23.3% vs 1.7% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 5% vs 1.7% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 0% vs 0% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 41.7% vs 17.9% wk 16 · n 12 · Phase 3 · secondary NCT04435600
  • 53.8% vs 17.9% wk 16 · n 13 · Phase 3 · secondary NCT04435600
  • 43.3% vs 17.9% wk 16 · n 30 · Phase 3 · secondary NCT04435600
  • 32.7% vs 0% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 22.4% vs 0% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 50% vs 17.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 41.5% vs 17.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 14% vs 17.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 45.8% vs 17.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481
sPGA 0/185.7% vs 7.1%+78.6 vs placebo100 mg · wk 16 · n 42NCT01483599
4 other results
  • 78.6% vs 7.1% 50 mg · wk 16 · n 42 · Phase 2 · primary NCT01483599
  • 83.3% vs 7.1% 200 mg · wk 16 · n 42 · Phase 2 · primary NCT01483599
  • 61% vs 7.1% 15 mg · wk 16 · n 41 · Phase 2 · primary NCT01483599
  • 34.1% vs 7.1% 5 mg · wk 16 · n 41 · Phase 2 · primary NCT01483599
87.8% vs 7.8%+80 vs placebowk 16 · n 304NCT02684370
28 other results
  • 83.5% vs 7% wk 16 · n 407 · Phase 3 · primary NCT02672852
  • 83.7% vs 5.1% wk 16 · n 294 · Phase 3 · primary NCT02684357
  • 78.1% vs 9.6% wk 16 · n 105 · Phase 3 · primary NCT03875482
  • 83.7% vs 60.2% wk 16 · n 301 · Phase 3 · primary NCT02694523
  • 79.6% vs 75% wk 16 · n 54 · Phase 3 · primary NCT04435600
  • 68.5% vs 67.9% wk 16 · n 54 · Phase 3 · primary NCT04435600
  • 83.3% vs 75% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 84.6% vs 75% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 90% vs 75% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 83.3% vs 67.9% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 84.6% vs 67.9% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 83.3% vs 67.9% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 32.2% vs 11.5% wk 16 · n 87 · Phase 3 · secondary NCT04713592
  • 87.8% vs 63% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 83.7% vs 61.6% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 82.2% vs 65% wk 12 · n 304 · Phase 3 · secondary NCT02684370
  • 82.3% vs 64.6% wk 12 · n 294 · Phase 3 · secondary NCT02684357
  • 91.7% vs 31.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 90% vs 33.3% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 81.7% vs 15% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 33.3% vs 3.3% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 75.4% vs 18.4% wk 16 · n 118 · Phase 4 · primary NCT04908475
  • 92.7% vs 10.3% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 86.2% vs 10.3% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 90.5% vs 67.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 90.2% vs 67.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 62.8% vs 67.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 90.4% vs 67.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481
DLQI, change-11.2 vs -2.6−8.6 vs placebo100 mg · wk 16 · n 495NCT02207244
10 other results
  • -11.2 vs -0.6 wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • -8.5 vs -0.8 100 mg · wk 16 · n 63 · Phase 3 · secondary NCT02325219
  • -7 vs -0.4 100 mg · wk 8 · n 63 · Phase 3 · secondary NCT02325219
  • -8.3 vs -0.8 50 mg · wk 16 · n 65 · Phase 3 · secondary NCT02325219
  • -7.5 vs -0.4 50 mg · wk 8 · n 65 · Phase 3 · secondary NCT02325219
  • -10.8 vs -2.3 100 mg · wk 16 · n 40 · Phase 2 · secondary NCT01483599
  • -11.1 vs -2.3 50 mg · wk 16 · n 40 · Phase 2 · secondary NCT01483599
  • -11.4 vs -2.3 200 mg · wk 16 · n 39 · Phase 2 · secondary NCT01483599
  • -10.3 vs -2.3 15 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • -6.2 vs -2.3 5 mg · wk 16 · n 39 · Phase 2 · secondary NCT01483599
-17 vs -9.7vs Fumadermwk 16 · n 59NCT03255382

PASI 75

guselkumab
84.1% vs 6.3%+77.8 vs placebo100 mg · wk 16 · n 63NCT02325219
11 other results
  • 89.2% vs 6.3% 50 mg · wk 16 · n 65 · Phase 3 · secondary NCT02325219
  • 86.3% vs 68.5% 100 mg · wk 16 · n 496 · Phase 3 · secondary NCT02207244
  • 92.7% vs 92.8% 100 mg · wk 16 · n 534 · Phase 3 · secondary NCT03090100
  • 89.3% vs 91.6% 100 mg · wk 12 · n 534 · Phase 3 · secondary NCT03090100
  • 91.2% vs 73.1% wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • 78.6% vs 4.8% 100 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 81% vs 4.8% 50 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 81% vs 4.8% 200 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 75.6% vs 4.8% 15 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • 43.9% vs 4.8% 5 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • 5.1% vs 22.9% wk 2 · n 507 · Phase 4 · secondary NCT03573323
risankizumab
85.2% vs 85.7%vs Ustekinumabwk 16 · n 54NCT04435600
19 other results
  • 83.3% vs 85.7% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 92.3% vs 85.7% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 86.7% vs 85.7% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 88.7% vs 8% wk 16 · n 407 · Phase 3 · secondary NCT02672852
  • 90.8% vs 6.1% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 90.7% vs 71.7% wk 16 · n 301 · Phase 3 · secondary NCT02694523
  • 86.8% vs 70% wk 12 · n 304 · Phase 3 · secondary NCT02684370
  • 88.8% vs 69.7% wk 12 · n 294 · Phase 3 · secondary NCT02684357
  • 93.3% vs 26.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 86.7% vs 20% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 75% vs 8.3% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 13.3% vs 3.3% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 94.5% vs 8.6% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 89.7% vs 8.6% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 90.5% vs 77.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 97.6% vs 77.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 67.4% vs 77.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 84.7% vs 18.8% wk 16 · n 118 · Phase 4 · secondary NCT04908475
  • 94% vs 77.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481

PASI 90

guselkumab
70% vs 2.4%+67.6 vs placebo100 mg · wk 16 · n 496NCT02207244
10 other results
  • 73.3% vs 2.9% wk 16 · n 329 · Phase 3 · primary NCT02207231
  • 69.8% vs 0% 100 mg · wk 16 · n 63 · Phase 3 · primary NCT02325219
  • 70.8% vs 0% 50 mg · wk 16 · n 65 · Phase 3 · primary NCT02325219
  • 75.8% vs 0% wk 16 · n 62 · Phase 3 · primary NCT02905331
  • 70% vs 46.8% 100 mg · wk 16 · n 496 · Phase 3 · secondary NCT02207244
  • 78.5% vs 79.6% 100 mg · wk 16 · n 534 · Phase 3 · secondary NCT03090100
  • 69.1% vs 76.1% 100 mg · wk 12 · n 534 · Phase 3 · secondary NCT03090100
  • 73.3% vs 49.7% wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • 35.9% vs 58.5% wk 8 · n 507 · Phase 4 · secondary NCT03573323
  • 7.9% vs 21% wk 4 · n 507 · Phase 4 · secondary NCT03573323
risankizumab
75.3% vs 4.9%+70.4 vs placebowk 16 · n 304NCT02684370
22 other results
  • 73.2% vs 2% wk 16 · n 407 · Phase 3 · primary NCT02672852
  • 74.8% vs 2% wk 16 · n 294 · Phase 3 · primary NCT02684357
  • 62.9% vs 3.8% wk 16 · n 105 · Phase 3 · primary NCT03875482
  • 72.4% vs 47.4% wk 16 · n 301 · Phase 3 · primary NCT02694523
  • 73.8% vs 65.6% wk 16 · n 164 · Phase 3 · primary NCT03478787
  • 75.3% vs 42% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 74.8% vs 47.5% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 64.8% vs 60.7% wk 16 · n 54 · Phase 3 · secondary NCT04435600
  • 76.7% vs 11.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 61.7% vs 5% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 38.3% vs 1.7% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 1.7% vs 0% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 83.3% vs 60.7% wk 16 · n 12 · Phase 3 · secondary NCT04435600
  • 84.6% vs 60.7% wk 16 · n 13 · Phase 3 · secondary NCT04435600
  • 76.7% vs 60.7% wk 16 · n 30 · Phase 3 · secondary NCT04435600
  • 74.5% vs 1.7% 150 mg · wk 16 · n 55 · Phase 2 · primary NCT03000075
  • 75.9% vs 1.7% 75 mg · wk 16 · n 58 · Phase 2 · primary NCT03000075
  • 81% vs 40% 180 mg · wk 12 · n 42 · Phase 2 · primary NCT02054481
  • 73.2% vs 40% 90 mg · wk 12 · n 41 · Phase 2 · primary NCT02054481
  • 32.6% vs 40% 18 mg · wk 12 · n 43 · Phase 2 · primary NCT02054481
  • 55.9% vs 5.1% wk 16 · n 118 · Phase 4 · primary NCT04908475
  • 77.1% vs 40% 90+180 mg · wk 12 · n 83 · Phase 2 · primary NCT02054481

PASI 100

guselkumab
50% vs 0%+50 vs placebowk 16 · n 62NCT02905331
3 other results
  • 24.9% vs 41.3% wk 12 · n 507 · Phase 4 · primary NCT03573323
  • 13.6% vs 29.6% wk 8 · n 507 · Phase 4 · secondary NCT03573323
  • 1.4% vs 6.7% wk 4 · n 507 · Phase 4 · secondary NCT03573323
risankizumab
35.9% vs 0%+35.9 vs placebowk 16 · n 304NCT02684370
20 other results
  • 47.2% vs 1% wk 16 · n 407 · Phase 3 · secondary NCT02672852
  • 50.7% vs 2% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 38.1% vs 1.9% wk 16 · n 105 · Phase 3 · secondary NCT03875482
  • 35.9% vs 12% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 50.7% vs 24.2% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 39.9% vs 23% wk 16 · n 301 · Phase 3 · secondary NCT02694523
  • 40.7% vs 17.9% wk 16 · n 54 · Phase 3 · secondary NCT04435600
  • 35% vs 1.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 23.3% vs 1.7% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 5% vs 1.7% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 0% vs 0% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 41.7% vs 17.9% wk 16 · n 12 · Phase 3 · secondary NCT04435600
  • 53.8% vs 17.9% wk 16 · n 13 · Phase 3 · secondary NCT04435600
  • 43.3% vs 17.9% wk 16 · n 30 · Phase 3 · secondary NCT04435600
  • 32.7% vs 0% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 22.4% vs 0% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 50% vs 17.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 41.5% vs 17.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 14% vs 17.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 45.8% vs 17.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481

sPGA 0/1

guselkumab
85.7% vs 7.1%+78.6 vs placebo100 mg · wk 16 · n 42NCT01483599
4 other results
  • 78.6% vs 7.1% 50 mg · wk 16 · n 42 · Phase 2 · primary NCT01483599
  • 83.3% vs 7.1% 200 mg · wk 16 · n 42 · Phase 2 · primary NCT01483599
  • 61% vs 7.1% 15 mg · wk 16 · n 41 · Phase 2 · primary NCT01483599
  • 34.1% vs 7.1% 5 mg · wk 16 · n 41 · Phase 2 · primary NCT01483599
risankizumab
87.8% vs 7.8%+80 vs placebowk 16 · n 304NCT02684370
28 other results
  • 83.5% vs 7% wk 16 · n 407 · Phase 3 · primary NCT02672852
  • 83.7% vs 5.1% wk 16 · n 294 · Phase 3 · primary NCT02684357
  • 78.1% vs 9.6% wk 16 · n 105 · Phase 3 · primary NCT03875482
  • 83.7% vs 60.2% wk 16 · n 301 · Phase 3 · primary NCT02694523
  • 79.6% vs 75% wk 16 · n 54 · Phase 3 · primary NCT04435600
  • 68.5% vs 67.9% wk 16 · n 54 · Phase 3 · primary NCT04435600
  • 83.3% vs 75% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 84.6% vs 75% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 90% vs 75% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 83.3% vs 67.9% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 84.6% vs 67.9% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 83.3% vs 67.9% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 32.2% vs 11.5% wk 16 · n 87 · Phase 3 · secondary NCT04713592
  • 87.8% vs 63% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 83.7% vs 61.6% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 82.2% vs 65% wk 12 · n 304 · Phase 3 · secondary NCT02684370
  • 82.3% vs 64.6% wk 12 · n 294 · Phase 3 · secondary NCT02684357
  • 91.7% vs 31.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 90% vs 33.3% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 81.7% vs 15% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 33.3% vs 3.3% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 75.4% vs 18.4% wk 16 · n 118 · Phase 4 · primary NCT04908475
  • 92.7% vs 10.3% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 86.2% vs 10.3% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 90.5% vs 67.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 90.2% vs 67.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 62.8% vs 67.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 90.4% vs 67.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481

DLQI, change

guselkumab
-11.2 vs -2.6−8.6 vs placebo100 mg · wk 16 · n 495NCT02207244
10 other results
  • -11.2 vs -0.6 wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • -8.5 vs -0.8 100 mg · wk 16 · n 63 · Phase 3 · secondary NCT02325219
  • -7 vs -0.4 100 mg · wk 8 · n 63 · Phase 3 · secondary NCT02325219
  • -8.3 vs -0.8 50 mg · wk 16 · n 65 · Phase 3 · secondary NCT02325219
  • -7.5 vs -0.4 50 mg · wk 8 · n 65 · Phase 3 · secondary NCT02325219
  • -10.8 vs -2.3 100 mg · wk 16 · n 40 · Phase 2 · secondary NCT01483599
  • -11.1 vs -2.3 50 mg · wk 16 · n 40 · Phase 2 · secondary NCT01483599
  • -11.4 vs -2.3 200 mg · wk 16 · n 39 · Phase 2 · secondary NCT01483599
  • -10.3 vs -2.3 15 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • -6.2 vs -2.3 5 mg · wk 16 · n 39 · Phase 2 · secondary NCT01483599
risankizumab
-17 vs -9.7vs Fumadermwk 16 · n 59NCT03255382
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
19 other shared endpoints and safety

Coverage. guselkumab: 23 of 23 rows · risankizumab: 23 of 23 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricguselkumab
Rows use multiple source trials
risankizumab
Rows use multiple source trials
BSA
absolute change · percentage points
Maintenance
-18.5% (n=59) vs -9.2% (n=57) Fumaric Acid Esters @ 24wka,b
NCT02951533 · Phase 3 · registry result, not featured evidence
-19.8% (n=60) vs -9.8% (n=58) Fumaderm @ 24wka,b
NCT03255382 · Phase 3 · registry result, not featured evidence
DLQI
absolute change · score
Maintenance
-15.2 vs -9.4 Fumaric Acid Esters score @ 24wka,b
NCT02951533 · Phase 3 · registry result, not featured evidence
-18.8 vs -11.2 Fumaderm score @ 24wka,b
NCT03255382 · Phase 3 · registry result, not featured evidence
DLQI 0/1
responder rate · % of participants
Induction
68.3% (n=60) vs 6.6% (n=61) placebo @ 16wk100 mgc,a,b
NCT02325219 · Phase 3 · registry result, not featured evidence
show 1 more dose
64.1% (n=64) vs 6.6% (n=61) placebo @ 16wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
65.8% (n=304) vs 7.8% (n=102) placebo @ 16wkc,a,b
NCT02684370 · Phase 3
show 1 more dose
65.8% (n=304) vs 43% (n=100) Ustekinumab @ 16wk
NCT02684370 · Phase 3
DLQI 0/1
responder rate · % of participants
Maintenance
61.7% (n=60) vs 16.9% (n=59) Fumaric Acid Esters @ 24wka,b
NCT02951533 · Phase 3 · registry result, not featured evidence
66.7% (n=60) vs 10% (n=60) Fumaderm @ 24wka,b
NCT03255382 · Phase 3 · registry result, not featured evidence
DLQI 0/1
responder rate · % of participants
No placebo or comparator arm
76.7% (n=60) @ 52wk100 mgc,a,b
NCT02325219 · Phase 3 · registry result, not featured evidence
show 1 more dose
73.4% (n=64) @ 52wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
47.1% (n=244) @ 52wk*a,b
NCT04102007 · Phase 3 · registry result, not featured evidence · converted to % from 115 Participants as posted
NAPSI
absolute change · score
Induction
-1.5 vs -0.2 placebo score @ 16wk100 mgc,a,b
NCT02325219 · Phase 3 · registry result, not featured evidence
show 1 more dose
-1.2 vs -0.2 placebo score @ 16wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
-13.6 vs -2.2 Fumaderm score @ 16wkc,a,b
NCT03255382 · Phase 3 · registry result, not featured evidence
show 1 more dose
-21.4 vs -4.2 Fumaderm score @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
PASI
percent change · % of baseline
Induction
91.53% (n=61) vs 8.72% (n=16) placebo @ 16wka,b
NCT02905331 · Phase 3
3 other source trials
88.7% (n=63) vs 0.2% (n=64) placebo @ 16wk100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
88.9% (n=65) vs 0.2% (n=64) placebo @ 16wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
93.65% (n=534) vs 93.94% (n=514) Secukinumab @ 16wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
-89.36% (n=101) vs -29.39% (n=50) placebo @ 16wka,b
NCT03875482 · Phase 3 · registry result, not featured evidence
PASI
absolute change · score
Induction
-23.9 vs -0.5 placebo score @ 16wk100 mgc,a,b
NCT02325219 · Phase 3 · registry result, not featured evidence
show 1 more dose
-22.6 vs -0.5 placebo score @ 16wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
-16.89 vs -9.11 Fumaderm score @ 16wka,b
NCT03255382 · Phase 3 · registry result, not featured evidence
PASI
percent change · % of baseline
No placebo or comparator arm
-84.49% (n=77) @ 16wk100 mga,b
NCT05272150 · Phase 3 · registry result, not featured evidence
1 other source trial
-82.6% (n=218) @ 16wk100 mg
NCT06039189 · Phase 3 · registry result, not featured evidence
-89.33% (n=107) @ 16wka,b
NCT03875508 · Phase 3 · registry result, not featured evidence
PASI 100
responder rate · % of participants
Maintenance
52.3% (n=507) vs 50% (n=520) Ixekizumab @ 24wkd,a,b
NCT03573323 · Phase 4 · registry result, not featured evidence
1 other source trial
31.7% (n=60) vs 3.4% (n=59) Fumaric Acid Esters @ 24wk
NCT02951533 · Phase 3 · registry result, not featured evidence
50% (n=60) vs 5% (n=60) Fumaderm @ 24wkd,a,b
NCT03255382 · Phase 3 · registry result, not featured evidence
PASI 100
responder rate · % of participants
No placebo or comparator arm
44.4% (n=880) @ 28wk100 mge,a,b
NCT03818035 · Phase 3 · registry result, not featured evidence
77.8% (n=9) @ 28wk*600 mgc,e,a,b
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
show 1 more dose
88.9% (n=9) @ 28wk*300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
PASI 50
responder rate · % of participants
Induction
9.3% (n=507) vs 27.5% (n=520) Ixekizumab @ 1wkd,a,b,f
NCT03573323 · Phase 4 · registry result, not featured evidence
91.7% (n=12) vs 92.9% (n=28) Ustekinumab @ 16wkc,d,a,b,f
NCT04435600 · Phase 3
show 3 more doses
90.7% (n=54) vs 92.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
100% (n=13) vs 92.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
96.7% (n=30) vs 92.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
PASI 75
responder rate · % of participants
Maintenance
90% (n=60) vs 27.1% (n=59) Fumaric Acid Esters @ 24wka,b
NCT02951533 · Phase 3 · registry result, not featured evidence
98.3% (n=60) vs 33.3% (n=60) Fumaderm @ 24wka,b
NCT03255382 · Phase 3 · registry result, not featured evidence
4 other source trials
55.8% (n=43) vs 70% (n=40) Stelara @ 24wk18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
92.9% (n=42) vs 70% (n=40) Stelara @ 24wk180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
92.7% (n=41) vs 70% (n=40) Stelara @ 24wk90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
92.8% (n=83) vs 70% (n=40) Stelara @ 24wk90+180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
PASI 90
responder rate · % of participants
Maintenance
75.2% (n=496) vs 54.8% (n=248) Adalimumab @ 24wk100 mga,b
NCT02207244 · Phase 3
2 other source trials
80.2% (n=329) vs 53% (n=334) Adalimumab @ 24wk
NCT02207231 · Phase 3
81.7% (n=60) vs 13.6% (n=59) Fumaric Acid Esters @ 24wk
NCT02951533 · Phase 3 · registry result, not featured evidence
83.3% (n=60) vs 10% (n=60) Fumaderm @ 24wka,b
NCT03255382 · Phase 3 · registry result, not featured evidence
4 other source trials
30.2% (n=43) vs 55% (n=40) Stelara @ 24wk18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
85.7% (n=42) vs 55% (n=40) Stelara @ 24wk180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
65.9% (n=41) vs 55% (n=40) Stelara @ 24wk90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
75.9% (n=83) vs 55% (n=40) Stelara @ 24wk90+180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
PASI 90
responder rate · % of participants
No placebo or comparator arm
57.1% (n=77) @ 16wk100 mga,b
NCT05272150 · Phase 3 · registry result, not featured evidence
1 other source trial
52.9% (n=225) @ 16wk100 mg
NCT06039189 · Phase 3 · registry result, not featured evidence
87.5% (n=8) @ 16wka,b
NCT04435600 · Phase 3
5 other source trials
100% (n=4) @ 16wk150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
60% (n=5) @ 16wk75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
75% (n=4) @ 16wk150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
100% (n=4) @ 16wk75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
66.7% (n=108) @ 16wk
NCT03875508 · Phase 3 · registry result, not featured evidence
PSSD Symptom
absolute change · score
Induction
-40.4 vs -8.3 placebo score @ 16wk100 mga,b
NCT02207244 · Phase 3
1 other source trial
-41.9 vs -3 placebo score @ 16wk
NCT02207231 · Phase 3
-6.402 vs -0.027 placebo score @ 16wka,b
NCT02684357 · Phase 3
Scalp IGA
responder rate · % of participants
Induction
82.8% (n=58) vs 10.5% (n=57) placebo @ 16wk100 mgc,g,a,b
NCT02325219 · Phase 3 · registry result, not featured evidence
show 1 more dose
74.1% (n=58) vs 10.5% (n=57) placebo @ 16wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
60.8% (n=51) vs 13% (n=54) placebo @ 16wkg,a,b
NCT05969223 · Phase 4
sPGA (0
responder rate · % of participants
Induction
25.2% (n=507) vs 41.9% (n=520) Ixekizumab @ 12wkd,a,b
NCT03573323 · Phase 4 · registry result, not featured evidence
21.7% (n=60) vs 3.3% (n=60) Fumaderm @ 12wkd,a,b
NCT03255382 · Phase 3 · registry result, not featured evidence
sPGA 0/1
responder rate · % of participants
Maintenance
76.9% (n=39) vs 48.6% (n=37) Adalimumab @ 40wk100 mgc,h,a,b,i
NCT01483599 · Phase 2 · registry result, not featured evidence
show 4 more doses
71.1% (n=38) vs 48.6% (n=37) Adalimumab @ 40wk50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
81.1% (n=37) vs 48.6% (n=37) Adalimumab @ 40wk200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
59.5% (n=37) vs 48.6% (n=37) Adalimumab @ 40wk15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
35.3% (n=34) vs 48.6% (n=37) Adalimumab @ 40wk5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
81.1% (n=111) vs 7.1% (n=225) placebo @ 104wkh,a,b,i
NCT02672852 · Phase 3
Dropout rate
—100 mgj
NCT02203032 · Phase 3
show 42 more results
3.6%100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207231 · Phase 3
—100 mg
NCT02207231 · Phase 3
1.6%Guselkumab
NCT02905331 · Phase 3
—Guselkumab (Week 0-16)
NCT02905331 · Phase 3
—Guselkumab (Week 16-40)
NCT02905331 · Phase 3
9.5%
NCT03573323 · Phase 4 · registry result, not featured evidence
13%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
4.9%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
7.6%100 mg
NCT06039189 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg
NCT03818035 · Phase 3 · registry result, not featured evidence
6.6%100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
1.6%100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
—50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
3.1%50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
—Part I/IIa (Week 0 to Week 32): Gu
NCT02951533 · Phase 3 · registry result, not featured evidence
—Part III (Week 64 Through Week 100
NCT02951533 · Phase 3 · registry result, not featured evidence
—Part IIb (Week 32 Through Week 56)
NCT02951533 · Phase 3 · registry result, not featured evidence
5.1%100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
4.8%100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
7.1%50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
9.5%200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
7.3%5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
1.6%Risankizumab (Part A)j
NCT02684370 · Phase 3
show 53 more results
—Risankizumab/Risankizumab (Part B)
NCT02684370 · Phase 3
1%Risankizumab (Part A1)
NCT02672852 · Phase 3
—Risankizumab/Risankizumab (Part B;
NCT02672852 · Phase 3
0%Part 1: Risankizumab
NCT04435600 · Phase 3
—Part 2 Period A Risankizumab Non-r
NCT04435600 · Phase 3
—Part 2 Period A Risankizumab Respo
NCT04435600 · Phase 3
—Part 2 Period A: Risankizumab
NCT04435600 · Phase 3
—Part 2 Period C: Risankizumab
NCT04435600 · Phase 3
—Part 3: Risankizumab
NCT04435600 · Phase 3
—Part 4: Risankizumab
NCT04435600 · Phase 3
0.7%Risankizumab (Part A)
NCT02684357 · Phase 3
—Risankizumab/Risankizumab (Part B)
NCT02684357 · Phase 3
—Adalimumab/Rerandomized to Risanki
NCT02694523 · Phase 3
—Adalimumab/Risankizumab (Part B)
NCT02694523 · Phase 3
2.3%Risankizumab (Part A)
NCT02694523 · Phase 3
—Risankizumab/Risankizumab (Part B)
NCT02694523 · Phase 3
1.8%Study-G Risankizumab (Period A)
NCT05969223 · Phase 4
—Study-G Risankizumab/Risankizumab
NCT05969223 · Phase 4
0%Study-S Risankizumab (Period A)
NCT05969223 · Phase 4
—Study-S Risankizumab/Risankizumab
NCT05969223 · Phase 4
—Period A: RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB, NR
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: RZB/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
26.2%150 mg
NCT03047395 · Phase 3 · registry result, not featured evidence
3.4%Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab (Double-blind Period)
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab (Open-la
NCT04713592 · Phase 3 · registry result, not featured evidence
16%
NCT04102007 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
11.1%
NCT03875508 · Phase 3 · registry result, not featured evidence
12.4%
NCT03875482 · Phase 3 · registry result, not featured evidence
7.9%
NCT03478787 · Phase 3 · registry result, not featured evidence
0%
NCT03255382 · Phase 3 · registry result, not featured evidence
70%600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
70%300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
—180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
—90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
4.8%180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
4.9%90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
9.3%18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—100 mgj
NCT02203032 · Phase 3
show 42 more results
1.8%100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207231 · Phase 3
—100 mg
NCT02207231 · Phase 3
0%Guselkumab
NCT02905331 · Phase 3
—Guselkumab (Week 0-16)
NCT02905331 · Phase 3
—Guselkumab (Week 16-40)
NCT02905331 · Phase 3
1.6%
NCT03573323 · Phase 4 · registry result, not featured evidence
1.3%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT06039189 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg
NCT03818035 · Phase 3 · registry result, not featured evidence
1.9%100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
—50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
1.5%50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
—Part I/IIa (Week 0 to Week 32): Gu
NCT02951533 · Phase 3 · registry result, not featured evidence
—Part III (Week 64 Through Week 100
NCT02951533 · Phase 3 · registry result, not featured evidence
—Part IIb (Week 32 Through Week 56)
NCT02951533 · Phase 3 · registry result, not featured evidence
1.7%100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
2.4%100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
2.4%50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
9.5%200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0.3%Risankizumab (Part A)j
NCT02684370 · Phase 3
show 53 more results
—Risankizumab/Risankizumab (Part B)
NCT02684370 · Phase 3
0.2%Risankizumab (Part A1)
NCT02672852 · Phase 3
—Risankizumab/Risankizumab (Part B;
NCT02672852 · Phase 3
—Part 1: Risankizumab
NCT04435600 · Phase 3
—Part 2 Period A Risankizumab Non-r
NCT04435600 · Phase 3
—Part 2 Period A Risankizumab Respo
NCT04435600 · Phase 3
—Part 2 Period A: Risankizumab
NCT04435600 · Phase 3
—Part 2 Period C: Risankizumab
NCT04435600 · Phase 3
—Part 3: Risankizumab
NCT04435600 · Phase 3
—Part 4: Risankizumab
NCT04435600 · Phase 3
0%Risankizumab (Part A)
NCT02684357 · Phase 3
—Risankizumab/Risankizumab (Part B)
NCT02684357 · Phase 3
—Adalimumab/Rerandomized to Risanki
NCT02694523 · Phase 3
—Adalimumab/Risankizumab (Part B)
NCT02694523 · Phase 3
1%Risankizumab (Part A)
NCT02694523 · Phase 3
—Risankizumab/Risankizumab (Part B)
NCT02694523 · Phase 3
—Study-G Risankizumab (Period A)
NCT05969223 · Phase 4
—Study-G Risankizumab/Risankizumab
NCT05969223 · Phase 4
—Study-S Risankizumab (Period A)
NCT05969223 · Phase 4
—Study-S Risankizumab/Risankizumab
NCT05969223 · Phase 4
—Period A: RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB, NR
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: RZB/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
6.5%150 mg
NCT03047395 · Phase 3 · registry result, not featured evidence
1.1%Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab (Double-blind Period)
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab (Open-la
NCT04713592 · Phase 3 · registry result, not featured evidence
1.6%
NCT04102007 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
0.9%
NCT03875508 · Phase 3 · registry result, not featured evidence
0%
NCT03875482 · Phase 3 · registry result, not featured evidence
0.6%
NCT03478787 · Phase 3 · registry result, not featured evidence
0%
NCT03255382 · Phase 3 · registry result, not featured evidence
—600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
—300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
—180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
—90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
2.4%90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
2.3%18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
Serious AEs
6.7%100 mgj
NCT02203032 · Phase 3
show 42 more results
1.6%100 mg
NCT02207244 · Phase 3
2.1%100 mg
NCT02207244 · Phase 3
14%100 mg
NCT02207244 · Phase 3
2.5%100 mg
NCT02207231 · Phase 3
2.4%100 mg
NCT02207231 · Phase 3
—Guselkumab
NCT02905331 · Phase 3
3.2%Guselkumab (Week 0-16)
NCT02905331 · Phase 3
1.6%Guselkumab (Week 16-40)
NCT02905331 · Phase 3
3.2%
NCT03573323 · Phase 4 · registry result, not featured evidence
3.9%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
3.7%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
5.3%100 mg
NCT06039189 · Phase 3 · registry result, not featured evidence
4.7%100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
6.3%100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
2.2%100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
3.5%100 mg
NCT03818035 · Phase 3 · registry result, not featured evidence
4.3%100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
0%100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
4%100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
6.6%100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
9.7%100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
1.6%100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
9.5%50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
1.5%50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
5%Part I/IIa (Week 0 to Week 32): Gu
NCT02951533 · Phase 3 · registry result, not featured evidence
0%Part III (Week 64 Through Week 100
NCT02951533 · Phase 3 · registry result, not featured evidence
5.5%Part IIb (Week 32 Through Week 56)
NCT02951533 · Phase 3 · registry result, not featured evidence
6.2%100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
5%100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
7.1%50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
5.3%5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
2.3%Risankizumab (Part A)j
NCT02684370 · Phase 3
show 53 more results
5.4%Risankizumab/Risankizumab (Part B)
NCT02684370 · Phase 3
2%Risankizumab (Part A1)
NCT02672852 · Phase 3
11.7%Risankizumab/Risankizumab (Part B;
NCT02672852 · Phase 3
0%Part 1: Risankizumab
NCT04435600 · Phase 3
10%Part 2 Period A Risankizumab Non-r
NCT04435600 · Phase 3
0%Part 2 Period A Risankizumab Respo
NCT04435600 · Phase 3
0%Part 2 Period A: Risankizumab
NCT04435600 · Phase 3
0%Part 2 Period C: Risankizumab
NCT04435600 · Phase 3
0%Part 3: Risankizumab
NCT04435600 · Phase 3
0%Part 4: Risankizumab
NCT04435600 · Phase 3
2%Risankizumab (Part A)
NCT02684357 · Phase 3
4.5%Risankizumab/Risankizumab (Part B)
NCT02684357 · Phase 3
5.7%Adalimumab/Rerandomized to Risanki
NCT02694523 · Phase 3
10.5%Adalimumab/Risankizumab (Part B)
NCT02694523 · Phase 3
3.3%Risankizumab (Part A)
NCT02694523 · Phase 3
4.1%Risankizumab/Risankizumab (Part B)
NCT02694523 · Phase 3
1.8%Study-G Risankizumab (Period A)
NCT05969223 · Phase 4
1.9%Study-G Risankizumab/Risankizumab
NCT05969223 · Phase 4
5.9%Study-S Risankizumab (Period A)
NCT05969223 · Phase 4
5.9%Study-S Risankizumab/Risankizumab
NCT05969223 · Phase 4
0.8%Period A: RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
0%Period B: APR/APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
2.9%Period B: APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB, NR
NCT04908475 · Phase 4 · registry result, not featured evidence
6.9%Period B: RZB/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
20%150 mg
NCT03047395 · Phase 3 · registry result, not featured evidence
—Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
5.7%Risankizumab (Double-blind Period)
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
6%Risankizumab/Risankizumab (Open-la
NCT04713592 · Phase 3 · registry result, not featured evidence
7%
NCT04102007 · Phase 3 · registry result, not featured evidence
25%150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
50%150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
20%75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
0%75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
5.6%
NCT03875508 · Phase 3 · registry result, not featured evidence
1%
NCT03875482 · Phase 3 · registry result, not featured evidence
5.5%
NCT03478787 · Phase 3 · registry result, not featured evidence
1.7%
NCT03255382 · Phase 3 · registry result, not featured evidence
0%600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
10%300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
8.7%180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
13.8%90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
3.6%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
1.9%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
7.4%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
3.4%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
1.8%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
14.6%90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
11.6%18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
100 mgj
nasopharyngitis 17%
upper respiratory tract infection 11.1%
NCT02203032 · Phase 3
show 37 more results
100 mg
nasopharyngitis 7.1% (placebo 6.5%)
headache 5.1% (placebo 2.8%)
upper respiratory tract infection 3.2% (placebo 4%)
NCT02207244 · Phase 3
100 mg
nasopharyngitis 3.7% (placebo 6.5%)
upper respiratory tract infection 2.5% (placebo 4%)
arthralgia 1.7% (placebo 2.4%)
NCT02207244 · Phase 3
100 mg
nasopharyngitis 30% (placebo 6.5%)
upper respiratory tract infection 23.5% (placebo 4%)
arthralgia 9.7% (placebo 2.4%)
NCT02207244 · Phase 3
100 mg
nasopharyngitis 20.1% (placebo 9.8%)
upper respiratory tract infection 9.6% (placebo 5.2%)
gastroenteritis 3.4% (placebo 1.1%)
NCT02207231 · Phase 3
100 mg
nasopharyngitis 9.1% (placebo 9.8%)
upper respiratory tract infection 7.6% (placebo 5.2%)
headache 4.3% (placebo 4%)
NCT02207231 · Phase 3
injection site pain 40.3% (placebo 43.8%)
injection site coldness 22.6% (placebo 18.8%)
injection site pruritus 12.9% (placebo 12.5%)
NCT02905331 · Phase 3
injection site pain 18% (placebo 43.8%)
injection site coldness 11.5% (placebo 18.8%)
viral upper respiratory tract infection 9.8% (placebo 0%)
NCT02905331 · Phase 3
upper respiratory tract infection 8.1%
nasopharyngitis 5.3%
injection site reaction 1.2%
NCT03573323 · Phase 4 · registry result, not featured evidence
100 mg
upper respiratory tract infection 16.9% (placebo 3.8%)
nasopharyngitis 11.7% (placebo 3.8%)
covid-19 6.5% (placebo 0%)
NCT05272150 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 24.7% (placebo 3.8%)
covid-19 16% (placebo 0%)
arthralgia 7.4% (placebo 0%)
NCT05272150 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 15.1% (placebo 2.7%)
nasopharyngitis 6.7% (placebo 7.1%)
covid-19 4.4% (placebo 0.9%)
NCT06039189 · Phase 3 · registry result, not featured evidence
100 mg Q8W
nasopharyngitis 17.6%
headache 5.4%
back pain 4.1%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg Q8W
nasopharyngitis 18.5%
hypertension 5.9%
arthralgia 5.5%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg Q8W
covid-19 14.7%
nasopharyngitis 12.5%
psoriasis 7.4%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 14.1%
covid-19 9.3%
headache 5.7%
NCT03818035 · Phase 3 · registry result, not featured evidence
100mg
nasopharyngitis 24.3%
headache 9%
hypertension 5.5%
NCT03818035 · Phase 3 · registry result, not featured evidence
100mg
nail psoriasis 22.2%
back pain 11.1%
covid-19 11.1%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg Q16W
nasopharyngitis 15.4%
headache 6%
back pain 5.4%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg Q16W
nasopharyngitis 12.4%
covid-19 8.8%
psoriasis 8.8%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 50% (placebo 10.9%)
eczema 11.3% (placebo 1.6%)
injection site erythema 11.3% (placebo 1.6%)
NCT02325219 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 12.7% (placebo 10.9%)
dental caries 3.2% (placebo 1.6%)
upper respiratory tract infection 3.2% (placebo 1.6%)
NCT02325219 · Phase 3 · registry result, not featured evidence
50 mg
nasopharyngitis 60.3% (placebo 10.9%)
arthralgia 14.3% (placebo 0%)
influenza 14.3% (placebo 1.6%)
NCT02325219 · Phase 3 · registry result, not featured evidence
50 mg
nasopharyngitis 21.5% (placebo 10.9%)
alopecia 3.1% (placebo 0%)
arthralgia 3.1% (placebo 0%)
NCT02325219 · Phase 3 · registry result, not featured evidence
nasopharyngitis 41.7%
headache 15%
diarrhoea 11.7%
NCT02951533 · Phase 3 · registry result, not featured evidence
aspartate aminotransferase increased 2.8%
tooth infection 2.8%
abdominal discomfort 0%
NCT02951533 · Phase 3 · registry result, not featured evidence
nasopharyngitis 50.9%
bronchitis 9.1%
alanine aminotransferase increased 5.5%
NCT02951533 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 22.1%
upper respiratory tract infection 15.5%
headache 9%
NCT03090100 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 10% (placebo 2.4%)
upper respiratory tract infection 7.5% (placebo 2.4%)
back pain 5% (placebo 0%)
NCT01483599 · Phase 2 · registry result, not featured evidence
100 mg
back pain 4.8% (placebo 0%)
headache 4.8% (placebo 2.4%)
sinusitis 4.8% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
50 mg
nasopharyngitis 17.9% (placebo 2.4%)
back pain 2.6% (placebo 0%)
headache 2.6% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
50 mg
hypertension 7.1% (placebo 2.4%)
fatigue 4.8% (placebo 7.1%)
arthralgia 2.4% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 13.2% (placebo 2.4%)
cough 5.3% (placebo 2.4%)
upper respiratory tract infection 5.3% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
200 mg
upper respiratory tract infection 7.3% (placebo 2.4%)
cough 4.9% (placebo 2.4%)
nasopharyngitis 4.9% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
15 mg
back pain 2.4% (placebo 0%)
nasopharyngitis 2.4% (placebo 2.4%)
sinusitis 2.4% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
15 mg
headache 9.8% (placebo 2.4%)
nasopharyngitis 9.8% (placebo 2.4%)
back pain 2.4% (placebo 0%)
NCT01483599 · Phase 2 · registry result, not featured evidence
5 mg
nasopharyngitis 15.8% (placebo 2.4%)
upper respiratory tract infection 10.5% (placebo 2.4%)
arthralgia 5.3% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
5 mg
nasopharyngitis 14.6% (placebo 2.4%)
back pain 7.3% (placebo 0%)
headache 7.3% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
j
viral upper respiratory tract infection 6.6% (placebo 5.9%)
upper respiratory tract infection 5.6% (placebo 2%)
headache 3% (placebo 2%)
NCT02684370 · Phase 3
show 48 more results
viral upper respiratory tract infection 13.5% (placebo 5.9%)
upper respiratory tract infection 10.1% (placebo 2%)
headache 1.7% (placebo 2%)
NCT02684370 · Phase 3
nasopharyngitis 5.2% (placebo 6%)
headache 3.4% (placebo 0%)
arthralgia 1.7% (placebo 2%)
NCT02672852 · Phase 3
nasopharyngitis 20.7% (placebo 6%)
upper respiratory tract infection 14.4% (placebo 5%)
arthralgia 9% (placebo 2%)
NCT02672852 · Phase 3
headache 16.7% (placebo 4.8%)
pyrexia 16.7% (placebo 0%)
abdominal pain 8.3% (placebo 0%)
NCT04435600 · Phase 3
nasopharyngitis 40% (placebo 9.5%)
covid-19 20% (placebo 9.5%)
conjunctivitis 10% (placebo 0%)
NCT04435600 · Phase 3
nasopharyngitis 22.7% (placebo 9.5%)
headache 18.2% (placebo 4.8%)
skin papilloma 13.6% (placebo 0%)
NCT04435600 · Phase 3
nasopharyngitis 18.5% (placebo 9.5%)
covid-19 9.3% (placebo 9.5%)
headache 5.6% (placebo 4.8%)
NCT04435600 · Phase 3
pyrexia 25% (placebo 0%)
bacterial vaginosis 12.5% (placebo 0%)
chills 12.5% (placebo 0%)
NCT04435600 · Phase 3
cough 15.4% (placebo 4.8%)
upper respiratory tract infection 15.4% (placebo 4.8%)
blood potassium increased 7.7% (placebo 0%)
NCT04435600 · Phase 3
nasopharyngitis 31.3% (placebo 9.5%)
pyrexia 12.5% (placebo 0%)
cough 9.4% (placebo 4.8%)
NCT04435600 · Phase 3
upper respiratory tract infection 3.7% (placebo 2%)
viral upper respiratory tract infection 3.4% (placebo 2%)
influenza 2% (placebo 1%)
NCT02684357 · Phase 3
viral upper respiratory tract infection 11.7% (placebo 2%)
upper respiratory tract infection 8.2% (placebo 2%)
diarrhoea 2.1% (placebo 3.1%)
NCT02684357 · Phase 3
viral upper respiratory tract infection 26.4%
upper respiratory tract infection 7.5%
headache 5.7%
NCT02694523 · Phase 3
viral upper respiratory tract infection 23.7%
hypertension 7.9%
upper respiratory tract infection 7.9%
NCT02694523 · Phase 3
viral upper respiratory tract infection 8.6%
upper respiratory tract infection 7%
headache 4%
NCT02694523 · Phase 3
viral upper respiratory tract infection 13.3%
upper respiratory tract infection 11.6%
hypertension 3.1%
NCT02694523 · Phase 3
upper respiratory tract infection 7.3% (placebo 3.7%)
covid-19 3.6% (placebo 3.7%)
nasopharyngitis 3.6% (placebo 3.7%)
NCT05969223 · Phase 4
upper respiratory tract infection 7.4% (placebo 3.7%)
covid-19 3.7% (placebo 3.7%)
nasopharyngitis 3.7% (placebo 3.7%)
NCT05969223 · Phase 4
upper respiratory tract infection 11.8% (placebo 3.7%)
covid-19 7.8% (placebo 3.7%)
nasopharyngitis 2% (placebo 3.7%)
NCT05969223 · Phase 4
upper respiratory tract infection 11.8% (placebo 3.7%)
covid-19 7.8% (placebo 3.7%)
nasopharyngitis 2% (placebo 3.7%)
NCT05969223 · Phase 4
covid-19 11%
nasopharyngitis 3.4%
headache 2.5%
NCT04908475 · Phase 4 · registry result, not featured evidence
covid-19 12.5%
nasopharyngitis 10.4%
hypertension 6.3%
NCT04908475 · Phase 4 · registry result, not featured evidence
covid-19 11.8%
nasopharyngitis 9.8%
upper respiratory tract infection 5.9%
NCT04908475 · Phase 4 · registry result, not featured evidence
covid-19 16.4%
nasopharyngitis 9.5%
hypertension 5.2%
NCT04908475 · Phase 4 · registry result, not featured evidence
150 mg
nasopharyngitis 22.1%
covid-19 16.6%
upper respiratory tract infection 14.4%
NCT03047395 · Phase 3 · registry result, not featured evidence
covid-19 2.3% (placebo 2.3%)
NCT04713592 · Phase 3 · registry result, not featured evidence
covid-19 14.3% (placebo 2.3%)
NCT04713592 · Phase 3 · registry result, not featured evidence
covid-19 8.6%
nasopharyngitis 5.7%
NCT04102007 · Phase 3 · registry result, not featured evidence
150 mg
viral upper respiratory tract infection 75%
otitis media 50%
acne 25%
NCT03022045 · Phase 3 · registry result, not featured evidence
150 mg
dehydration 50%
abdominal pain upper 25%
acne 25%
NCT03022045 · Phase 3 · registry result, not featured evidence
75 mg
viral upper respiratory tract infection 60%
constipation 20%
diarrhoea 20%
NCT03022045 · Phase 3 · registry result, not featured evidence
75 mg
alanine aminotransferase increased 25%
aspartate aminotransferase increased 25%
erythema 25%
NCT03022045 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.4%
upper respiratory tract infection 5.6%
NCT03875508 · Phase 3 · registry result, not featured evidence
nasopharyngitis 21.3%
upper respiratory tract infection 12.8%
arthralgia 5.5%
NCT03478787 · Phase 3 · registry result, not featured evidence
nasopharyngitis 58.3%
headache 8.3%
oropharyngeal pain 8.3%
NCT03255382 · Phase 3 · registry result, not featured evidence
600 mg
upper respiratory infection 50%
common cold 30%
covid-19 infection 30%
NCT05283135 · Phase 2 · registry result, not featured evidence
300 mg
upper respiratory infection 20%
bleeding internal hemorrhoids 10%
bursitis, left elbow 10%
NCT05283135 · Phase 2 · registry result, not featured evidence
180 mg
upper respiratory tract infection 17.4%
dermatitis contact 13%
nasopharyngitis 13%
NCT02203851 · Phase 2 · registry result, not featured evidence
90 mg
nasopharyngitis 18.4%
upper respiratory tract infection 12.6%
arthralgia 10.3%
NCT02203851 · Phase 2 · registry result, not featured evidence
150 mg
nasopharyngitis 29.6% (placebo 13.8%)
arthralgia 11.1% (placebo 1.7%)
oral herpes 7.4% (placebo 0%)
NCT03000075 · Phase 2 · registry result, not featured evidence
150 mg
nasopharyngitis 18.2% (placebo 13.8%)
arthralgia 3.6% (placebo 1.7%)
back pain 1.8% (placebo 1.7%)
NCT03000075 · Phase 2 · registry result, not featured evidence
150 mg
nasopharyngitis 20.4% (placebo 13.8%)
dental caries 7.4% (placebo 1.7%)
blood triglycerides increased 5.6% (placebo 0%)
NCT03000075 · Phase 2 · registry result, not featured evidence
75 mg
nasopharyngitis 29.6% (placebo 13.8%)
arthralgia 11.1% (placebo 1.7%)
asteatosis 7.4% (placebo 0%)
NCT03000075 · Phase 2 · registry result, not featured evidence
75 mg
diabetes mellitus 5.2% (placebo 1.7%)
nasopharyngitis 5.2% (placebo 13.8%)
back pain 3.4% (placebo 1.7%)
NCT03000075 · Phase 2 · registry result, not featured evidence
75 mg
nasopharyngitis 21.4% (placebo 13.8%)
hepatic function abnormal 5.4% (placebo 0%)
influenza 5.4% (placebo 0%)
NCT03000075 · Phase 2 · registry result, not featured evidence
180 mg
nasopharyngitis 26.2%
arthralgia 7.1%
headache 7.1%
NCT02054481 · Phase 2 · registry result, not featured evidence
90 mg
nasopharyngitis 34.1%
back pain 9.8%
gastroenteritis 9.8%
NCT02054481 · Phase 2 · registry result, not featured evidence
18 mg
nasopharyngitis 34.9%
headache 11.6%
folliculitis 7%
NCT02054481 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dTrial phases differ: Phase 3 versus Phase 4.
  5. eTrial phases differ: Phase 2 versus Phase 3.
  6. fAssessment timepoints differ: 16 weeks versus 1 weeks.
  7. gTrial phases differ: Phase 4 versus Phase 3.
  8. hTrial phases differ: Phase 3 versus Phase 2.
  9. iAssessment timepoints differ: 104 weeks versus 40 weeks.
  10. jPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

guselkumab

IGA 0 1 Response Visits 1.5 vs 0.7 Ustekinumab visits
event count · visits
NCT02203032 · Phase 3
PASI90 Response Visits 2.2 vs 1.1 Ustekinumab visits
event count · visits
NCT02203032 · Phase 3
IGA 0 Response Visits 0.9 vs 0.4 Ustekinumab visits
event count · visits
NCT02203032 · Phase 3
IGA 0/1 84.1% (n=496) vs 8.5% (n=248) placebo @ 16wk100 mg
responder rate · % of participants
NCT02207244 · Phase 3
show 13 more results
83.5% (n=496) vs 64.9% (n=248) Adalimumab @ 24wk100 mg
NCT02207244 · Phase 3
84.1% (n=496) vs 67.7% (n=248) Adalimumab @ 16wk100 mg
NCT02207244 · Phase 3
88.9% (n=63) vs 7.8% (n=64) placebo @ 16wk100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
85% (n=534) vs 74.9% (n=514) Secukinumab @ 48wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
86.7% (n=534) vs 86.6% (n=514) Secukinumab @ 16wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
85.6% (n=534) vs 86.4% (n=514) Secukinumab @ 12wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
92.3% (n=65) vs 7.8% (n=64) placebo @ 16wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
31.1% (n=135) vs 14.3% (n=133) Ustekinumab @ 28wk
NCT02203032 · Phase 3
85.1% (n=329) vs 6.9% (n=174) placebo @ 16wk
NCT02207231 · Phase 3
84.2% (n=329) vs 61.7% (n=334) Adalimumab @ 24wk
NCT02207231 · Phase 3
80.5% (n=329) vs 55.4% (n=334) Adalimumab @ 48wk
NCT02207231 · Phase 3
85.1% (n=329) vs 65.9% (n=334) Adalimumab @ 16wk
NCT02207231 · Phase 3
80.6% (n=62) vs 0% (n=16) placebo @ 16wk
NCT02905331 · Phase 3
IGA 0 51.8% (n=496) vs 31.5% (n=248) Adalimumab @ 24wk100 mg
responder rate · % of participants
NCT02207244 · Phase 3
show 5 more results
62.2% (n=534) vs 50.4% (n=514) Secukinumab @ 48wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
52.6% (n=329) vs 29.3% (n=334) Adalimumab @ 24wk
NCT02207231 · Phase 3
50.5% (n=329) vs 25.7% (n=334) Adalimumab @ 48wk
NCT02207231 · Phase 3
56.5% (n=62) vs 0% (n=16) placebo @ 16wk
NCT02905331 · Phase 3
51.7% (n=60) vs 6.8% (n=59) Fumaric Acid Esters @ 24wk
NCT02951533 · Phase 3 · registry result, not featured evidence
PASI 90 Response Maintenance 72.3% (n=534) vs 64.4% (n=514) Secukinumab @ 48wk100 mg
responder rate · % of participants
NCT03090100 · Phase 3 · registry result, not featured evidence
show 5 more results
71% (n=534) vs 61.5% (n=514) Secukinumab @ 48wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
92.1% (n=419) vs 80.9% (n=409) Secukinumab @ 48wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
81.8% (n=193) vs 35.4% (n=181) placebo @ 48wk
NCT02207244 · Phase 3
86% (n=193) vs 11.5% (n=181) placebo @ 72wk
NCT02207244 · Phase 3
85.2% (n=54) vs 35.7% (n=14) Fumaric Acid Esters @ 56wk
NCT02951533 · Phase 3 · registry result, not featured evidence
Ss-IGA 0 1 80.6% (n=408) vs 10.9% (n=202) placebo @ 16wk100 mg
responder rate · % of participants
NCT02207244 · Phase 3
show 1 more result
83.4% (n=277) vs 14.5% (n=145) placebo @ 16wk
NCT02207231 · Phase 3
IGA Leq2 93.5% (n=62) vs 0% (n=16) placebo @ 16wk
responder rate · % of participants
NCT02905331 · Phase 3
PASI 50 93.5% (n=62) vs 0% (n=16) placebo @ 16wk
responder rate · % of participants
PASI 50 responders
NCT02905331 · Phase 3
PASI 75 88.7% (n=62) vs 0% (n=16) placebo @ 16wk
responder rate · % of participants
PASI 75 responders
NCT02905331 · Phase 3
IGA 0/1 74% (n=77) @ 16wk100 mg
responder rate · % of participants
No placebo or comparator arm
NCT05272150 · Phase 3 · registry result, not featured evidence
show 2 more results
74.2% (n=225) @ 16wk100 mg
NCT06039189 · Phase 3 · registry result, not featured evidence
30.6% (n=36) @ 100wk
NCT02951533 · Phase 3 · registry result, not featured evidence
Ss-IGA 0 1 68.4% (n=76) @ 16wk100 mg
responder rate · % of participants
No placebo or comparator arm
NCT05272150 · Phase 3 · registry result, not featured evidence
show 2 more results
75% (n=152) @ 16wk100 mg
NCT06039189 · Phase 3 · registry result, not featured evidence
32.4% (n=34) @ 100wk
NCT02951533 · Phase 3 · registry result, not featured evidence

+ 80 further endpoints in the CSV export.

risankizumab

PSS Total -5.608 vs 0.157 placebo score @ 16wk
absolute change · score
NCT02684370 · Phase 3
show 3 more results
-6.013 vs -1.036 placebo score @ 16wk
NCT05969223 · Phase 4
-8.7 vs -5.5 Fumaderm score @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
-9.5 vs -5.6 Fumaderm score @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
sPGA 0/1 88.9% (n=27) @ 52wk150 mg
responder rate · % of participants
No placebo or comparator arm
NCT03000075 · Phase 2 · registry result, not featured evidence
show 12 more results
94.5% (n=55) @ 52wk150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
96.3% (n=27) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
84.5% (n=58) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
68.8% (n=32) @ 48wk180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
70.4% (n=27) @ 48wk90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
63.6% (n=22) @ 48wk18 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
62.5% (n=8) @ 16wk
NCT04435600 · Phase 3
62.5% (n=8) @ 16wk
NCT04435600 · Phase 3
57.4% (n=244) @ 16wk*
NCT04102007 · Phase 3 · registry result, not featured evidence · converted to % from 140 Participants as posted
62.3% (n=244) @ 52wk*
NCT04102007 · Phase 3 · registry result, not featured evidence · converted to % from 152 Participants as posted
81.5% (n=108) @ 16wk
NCT03875508 · Phase 3 · registry result, not featured evidence
66.7% (n=27) @ 48wk
NCT02203851 · Phase 2 · registry result, not featured evidence
PASI 50 100% (n=32) @ 48wk180 mg
responder rate · % of participants
No placebo or comparator arm
NCT02203851 · Phase 2 · registry result, not featured evidence
show 4 more results
96.3% (n=27) @ 48wk90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
95.5% (n=22) @ 48wk18 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
87.5% (n=8) @ 16wk
NCT04435600 · Phase 3
100% (n=27) @ 48wk
NCT02203851 · Phase 2 · registry result, not featured evidence
PASI 75 88.9% (n=27) @ 52wk150 mg
responder rate · % of participants
No placebo or comparator arm
NCT03000075 · Phase 2 · registry result, not featured evidence
show 9 more results
96.4% (n=55) @ 52wk150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
100% (n=27) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
94.8% (n=58) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
90.6% (n=32) @ 48wk180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
92.6% (n=27) @ 48wk90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
86.4% (n=22) @ 48wk18 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
87.5% (n=8) @ 16wk
NCT04435600 · Phase 3
84.3% (n=108) @ 16wk
NCT03875508 · Phase 3 · registry result, not featured evidence
96.3% (n=27) @ 48wk
NCT02203851 · Phase 2 · registry result, not featured evidence
CDLQI -7.4 vs -6.8 Ustekinumab score @ 16wk
absolute change · score
NCT04435600 · Phase 3
CDLQI -7.5 score @ 16wk
absolute change · score
No placebo or comparator arm
NCT04435600 · Phase 3
FDLQI -6.9 vs -6 Ustekinumab score @ 16wk
absolute change · score
NCT04435600 · Phase 3
FDLQI -5.8 score @ 16wk
absolute change · score
No placebo or comparator arm
NCT04435600 · Phase 3
Itch NRS -3.8 vs -2.9 Ustekinumab score @ 16wk
absolute change · score
NCT04435600 · Phase 3
Itch NRS -2.8 score @ 16wk
absolute change · score
No placebo or comparator arm
NCT04435600 · Phase 3
Itch NRS 4-Point Improvement 64.9% (n=37) vs 57.1% (n=14) Ustekinumab @ 16wk
responder rate · % of participants
NCT04435600 · Phase 3
show 1 more result
48.8% (n=41) vs 6.7% (n=45) placebo @ 16wk
NCT05969223 · Phase 4
sPGA-G 0 1 69.1% (n=55) vs 13% (n=54) placebo @ 16wk
responder rate · % of participants
NCT05969223 · Phase 4

+ 28 further endpoints in the CSV export.

Ulcerative Colitis

Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline

guselkumab · Tremfya

Marketed by Johnson & Johnson

Approved in Ulcerative Colitismonoclonal antibody
Reliable signal

QUASAR/GALAXI · Phase 3 · completed

Only IL-23i to beat ustekinumab head-to-head on endoscopy in a registrational trial — strong differentiator.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2027 · NCT06260163 (registry estimate)

Reported efficacy

Percentage of Participants in Clinical Remission at Week 12: Percentage of Participants in Clinical Remission at Week 12 (Week 12): Placebo 6.5 Percentage of participants (95% CI 2.4 to 10.6) | Combined Guselkumab 400 mg 27.6 Percentage of participants (95% CI 22.4 to 32.8) (met)

Result source: NCT05528510

risankizumab · Skyrizi

Marketed by AbbVie and partners

Approved in Ulcerative Colitismonoclonal antibody
Reliable signal

NCT03398148 · Phase 2/3 · completed

Design meets the 'strong' test: randomized, double-blind (participant and investigator masked), placebo-controlled, large adequately powered sample (n=1555 treated), hard clinical/endoscopic composite endpoint (Adapted Mayo Score remission including endoscopic subscore), and the primary comparison was statistically significant in the favorable direction for all randomized dose arms in both substudies.

Next expected readout: August 2027 · NCT06880744 (registry estimate)

Reported efficacy

clinical remission + endoscopic improvement met (met)

Result source: INSPIRE/COMMAND

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointguselkumabrisankizumab
Clinical remission (induction)22.6% vs 7.9%+14.7 vs placebo200 mg IV · wk 12 · n 421NCT04033445
2 other results
  • 21.1% vs 22.2% wk 12 · n 71 · Phase 2 · secondary NCT03662542
  • 36.6% vs 22.2% wk 12 · n 71 · Phase 2 · secondary NCT03662542
20.3% vs 6.2%+14.1 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
4 other results
  • 12.4% vs 1.7% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · primary NCT03398148
  • 9.8% vs 1.7% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148
  • 10.3% vs 1.7% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · primary NCT03398148
  • 11.5% vs 1.7% 600 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148
Clinical remission (maintenance)50% vs 18.9%+31.1 vs placebo200 mg SC q4w · wk 44 · n 190NCT04033445
1 other result
  • 45.2% vs 18.9% 100 mg SC q8w · wk 44 · n 188 · Phase 3 · primary NCT04033445
—Trial running · NCT03398135
Clinical response (induction)61.4% vs 27.6%+33.8 vs placebo200 mg IV · wk 12 · n 101NCT04033445
3 other results
  • 60.7% vs 27.6% 400 mg IV · wk 12 · n 107 · Phase 3 · primary NCT04033445
  • 74.6% vs 61.1% wk 12 · n 71 · Phase 2 · primary NCT03662542
  • 83.1% vs 61.1% wk 12 · n 71 · Phase 2 · primary NCT03662542
64.3% vs 35.7%+28.6 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
9 other results
  • 52.2% vs 30.5% 1200 mg IV · wk 4 · n 650 · Phase 2/3 · secondary NCT03398148
  • 46.2% vs 20% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · secondary NCT03398148
  • 43.5% vs 25% 1800 mg IV · wk 4 · n 340 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 20% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 25% 1200 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148
  • 53.4% vs 20% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · secondary NCT03398148
  • 37.9% vs 25% 1800 mg IV · wk 4 · n 58 · Phase 2/3 · secondary NCT03398148
  • 42.6% vs 20% 600 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 32.8% vs 25% 600 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148
Endoscopic improvement (induction)—Trial running · NCT0403344536.5% vs 12.1%+24.4 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
Corticosteroid-free remission (maintenance)—Trial running · NCT04033445—Trial running · NCT03398135

Clinical remission (induction)

guselkumab
22.6% vs 7.9%+14.7 vs placebo200 mg IV · wk 12 · n 421NCT04033445
2 other results
  • 21.1% vs 22.2% wk 12 · n 71 · Phase 2 · secondary NCT03662542
  • 36.6% vs 22.2% wk 12 · n 71 · Phase 2 · secondary NCT03662542
risankizumab
20.3% vs 6.2%+14.1 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
4 other results
  • 12.4% vs 1.7% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · primary NCT03398148
  • 9.8% vs 1.7% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148
  • 10.3% vs 1.7% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · primary NCT03398148
  • 11.5% vs 1.7% 600 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148

Clinical remission (maintenance)

guselkumab
50% vs 18.9%+31.1 vs placebo200 mg SC q4w · wk 44 · n 190NCT04033445
1 other result
  • 45.2% vs 18.9% 100 mg SC q8w · wk 44 · n 188 · Phase 3 · primary NCT04033445
risankizumab
—Trial running · NCT03398135

Clinical response (induction)

guselkumab
61.4% vs 27.6%+33.8 vs placebo200 mg IV · wk 12 · n 101NCT04033445
3 other results
  • 60.7% vs 27.6% 400 mg IV · wk 12 · n 107 · Phase 3 · primary NCT04033445
  • 74.6% vs 61.1% wk 12 · n 71 · Phase 2 · primary NCT03662542
  • 83.1% vs 61.1% wk 12 · n 71 · Phase 2 · primary NCT03662542
risankizumab
64.3% vs 35.7%+28.6 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
9 other results
  • 52.2% vs 30.5% 1200 mg IV · wk 4 · n 650 · Phase 2/3 · secondary NCT03398148
  • 46.2% vs 20% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · secondary NCT03398148
  • 43.5% vs 25% 1800 mg IV · wk 4 · n 340 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 20% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 25% 1200 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148
  • 53.4% vs 20% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · secondary NCT03398148
  • 37.9% vs 25% 1800 mg IV · wk 4 · n 58 · Phase 2/3 · secondary NCT03398148
  • 42.6% vs 20% 600 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 32.8% vs 25% 600 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148

Endoscopic improvement (induction)

guselkumab
—Trial running · NCT04033445
risankizumab
36.5% vs 12.1%+24.4 vs placebo1200 mg IV · wk 12 · n 650NCT03398148

Corticosteroid-free remission (maintenance)

guselkumab
—Trial running · NCT04033445
risankizumab
—Trial running · NCT03398135
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. guselkumab: 4 of 4 rows · risankizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricguselkumabrisankizumab
Dropout rate
2.8%200 mg IVa
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 17 more results
—200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
4.1%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—100 mg SC q8w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—100 mg SC q8w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
0.9%400 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
0%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
1.4%Combination Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Safety Follow-up: Guselkumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
4.9%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 13 more results
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1.7%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
10.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
9.8%600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
Discontinued due to AEs
0.9%200 mg IVa
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 17 more results
—200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
1.6%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—100 mg SC q8w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—100 mg SC q8w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
0%400 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
0%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
1.4%Combination Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Safety Follow-up: Guselkumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
3.3%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 13 more results
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
0%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
2.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
3.3%600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
Serious AEs
0.9%200 mg IVa
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 17 more results
3%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
3.8%200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
3%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
2.3%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
2.3%200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
6.5%200 mg SC q4w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
5.6%200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
6%200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
4.3%100 mg SC q8w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
2.5%100 mg SC q8w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
2.7%400 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
1.4%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
2.8%Combination Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
4.2%Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
1.4%Monotherapy Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
0%Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
3.1%Safety Follow-up: Guselkumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
6.6%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 13 more results
2.6%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1.5%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
2.3%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
9.9%360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1.4%360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.5%180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
5.6%180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.6%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
2.7%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
9.7%600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
Most frequent reported AEs
200 mg IVa
anaemia 7.4% (placebo 10.2%)
covid-19 5.6% (placebo 4.6%)
abdominal pain 3.7% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 17 more results
200 mg IV
anaemia 6% (placebo 10.2%)
upper respiratory tract infection 4.5% (placebo 0%)
colitis ulcerative 3% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC
colitis ulcerative 3.8% (placebo 2.8%)
headache 3.8% (placebo 7.4%)
anaemia 2.5% (placebo 10.2%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg IV
anaemia 5% (placebo 10.2%)
covid-19 5% (placebo 4.6%)
headache 3% (placebo 7.4%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg IV
covid-19 7.6% (placebo 4.6%)
colitis ulcerative 4.1% (placebo 2.8%)
nasopharyngitis 2.9% (placebo 1.9%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC
covid-19 7% (placebo 4.6%)
colitis ulcerative 5.4% (placebo 2.8%)
anaemia 4.7% (placebo 10.2%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC q4w to 200 mg SC q4w
colitis ulcerative 16.1% (placebo 2.8%)
covid-19 6.5% (placebo 4.6%)
abdominal pain 3.2% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC q4w
covid-19 18.4% (placebo 4.6%)
colitis ulcerative 16.8% (placebo 2.8%)
pyrexia 6.4% (placebo 4.6%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC q4w
colitis ulcerative 13.1% (placebo 2.8%)
covid-19 10.1% (placebo 4.6%)
arthralgia 8% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
100 mg SC q8w to 200 mg SC q4w
covid-19 13% (placebo 4.6%)
anaemia 8.7% (placebo 10.2%)
colitis ulcerative 8.7% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
100 mg SC q8w
covid-19 14.2% (placebo 4.6%)
colitis ulcerative 10.2% (placebo 2.8%)
arthralgia 6.1% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
400 mg IV
anaemia 8.1% (placebo 10.2%)
headache 5.4% (placebo 7.4%)
arthralgia 3.6% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
anaemia 5.6%
colitis ulcerative 5.6%
headache 5.6%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
anaemia 8.5%
upper respiratory tract infection 7%
neutropenia 5.6%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
colitis ulcerative 8.5%
upper respiratory tract infection 8.5%
headache 4.2%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
anaemia 8.6%
headache 7.1%
colitis ulcerative 5.7%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
anaemia 0%
colitis ulcerative 0%
headache 0%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
anaemia 1.5%
colitis ulcerative 1.5%
headache 0%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
1200 mg IV
colitis ulcerative 4.9% (placebo 8.5%)
headache 4.9% (placebo 5.1%)
nasopharyngitis 4.9% (placebo 6.8%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 12 more results
1200 mg IV
covid-19 4.6% (placebo 0%)
anaemia 3.2% (placebo 3.4%)
headache 2.9% (placebo 5.1%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1200 mg IV
covid-19 5.9% (placebo 0%)
headache 2.9% (placebo 5.1%)
anaemia 1.5% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1200 mg IV
covid-19 5.7% (placebo 0%)
anaemia 2.9% (placebo 3.4%)
colitis ulcerative 1.7% (placebo 8.5%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
360 mg SC
nasopharyngitis 8.5% (placebo 6.8%)
headache 7% (placebo 5.1%)
colitis ulcerative 4.2% (placebo 8.5%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
360 mg SC
anaemia 8.5% (placebo 3.4%)
covid-19 8.5% (placebo 0%)
headache 8.5% (placebo 5.1%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
180 mg SC
headache 2.8% (placebo 5.1%)
anaemia 1.4% (placebo 3.4%)
nasopharyngitis 1.4% (placebo 6.8%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
180 mg SC
covid-19 5.6% (placebo 0%)
colitis ulcerative 4.2% (placebo 8.5%)
anaemia 2.8% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
nasopharyngitis 8.6% (placebo 6.8%)
headache 6.9% (placebo 5.1%)
anaemia 1.7% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
nasopharyngitis 7% (placebo 6.8%)
headache 6.5% (placebo 5.1%)
anaemia 3.5% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
nasopharyngitis 10.8% (placebo 6.8%)
anaemia 2.7% (placebo 3.4%)
colitis ulcerative 2.7% (placebo 8.5%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
dry skin 5.6% (placebo 0%)
headache 5.6% (placebo 5.1%)
nasopharyngitis 5.6% (placebo 6.8%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
600 mg IV
nasopharyngitis 8.1% (placebo 6.8%)
bronchitis 6.5% (placebo 0%)
dry skin 3.2% (placebo 0%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3

Notes

  1. aPopulation comparability has not been reviewed for 6 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

guselkumab

Clinical Response 61.4% (n=101) vs 27.6% (n=105) placebo @ 12wk200 mg IV
responder rate · % of participants
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 3 more results
60.7% (n=107) vs 27.6% (n=105) placebo @ 12wk400 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
74.6% (n=71) vs 61.1% (n=72) Golimumab @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
83.1% (n=71) vs 61.1% (n=72) Golimumab @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
Clinical Remission 22.6% (n=421) vs 7.9% (n=280) placebo @ 12wk200 mg IV
responder rate · % of participants
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 4 more results
50% (n=190) vs 18.9% (n=190) placebo @ 44wk200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
45.2% (n=188) vs 18.9% (n=190) placebo @ 44wk100 mg SC q8w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
21.1% (n=71) vs 22.2% (n=72) Golimumab @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
36.6% (n=71) vs 22.2% (n=72) Golimumab @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · combination

risankizumab

Clinical Remission 9.8% (n=61) vs 1.7% (n=60) placebo @ 12wk1200 mg IV
responder rate · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 6 Participants as posted
show 4 more results
20.3% (n=650) vs 6.2% (n=325) placebo @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
10.3% (n=58) vs 1.7% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 6 Participants as posted
12.4% (n=340) vs 1.7% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 42 Participants as posted
11.5% (n=61) vs 1.7% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 7 Participants as posted
Endoscopic Improvement 13.1% (n=61) vs 5% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 8 Participants as posted
show 3 more results
15.5% (n=58) vs 5% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 9 Participants as posted
17.9% (n=340) vs 5% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 61 Participants as posted
24.6% (n=61) vs 5% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 15 Participants as posted
Clinical Response 45.9% (n=61) vs 20% (n=60) placebo @ 12wk1200 mg IV
responder rate · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 28 Participants as posted
show 9 more results
45.9% (n=61) vs 25% (n=60) placebo @ 4wk*1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 28 Participants as posted
64.3% (n=650) vs 35.7% (n=325) placebo @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
52.2% (n=650) vs 30.5% (n=325) placebo @ 4wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
53.4% (n=58) vs 20% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 31 Participants as posted
46.2% (n=340) vs 20% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 157 Participants as posted
37.9% (n=58) vs 25% (n=60) placebo @ 4wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 22 Participants as posted
43.5% (n=340) vs 25% (n=60) placebo @ 4wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 148 Participants as posted
42.6% (n=61) vs 20% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 26 Participants as posted
32.8% (n=61) vs 25% (n=60) placebo @ 4wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 20 Participants as posted
Endoscopic Remission 4.9% (n=61) vs 0% (n=60) placebo @ 12wk1200 mg IV
responder rate · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 3 Participants as posted
show 4 more results
10.6% (n=650) vs 3.4% (n=325) placebo @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.6% (n=58) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 5 Participants as posted
6.5% (n=340) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 22 Participants as posted
8.2% (n=61) vs 0% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 5 Participants as posted
UC-related Hospitalization 6.6% (n=61) vs 8.3% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 4 Participants as posted
show 3 more results
5.2% (n=58) vs 8.3% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 3 Participants as posted
5.6% (n=340) vs 8.3% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 19 Participants as posted
9.8% (n=61) vs 8.3% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 6 Participants as posted
HEMR 3.3% (n=61) vs 0% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 2 Participants as posted
show 3 more results
1.7% (n=58) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 1 Participants as posted
2.9% (n=340) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 10 Participants as posted
4.9% (n=61) vs 0% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 3 Participants as posted
UC-SQ -15.6 vs -7.4 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 3 more results
-15.1 vs -7.4 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
-17.1 vs -7.4 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
-13.8 vs -7.4 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
IBDQ 40.3 vs 20.1 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 4 more results
42.6 vs 24.3 placebo score @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
40 vs 20.1 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
49.5 vs 20.1 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
37.4 vs 20.1 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
SF-36 PCS 6.35 vs 3.904 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 3 more results
6.296 vs 3.904 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.719 vs 3.904 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
5.112 vs 3.904 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
SF-36 MCS 7.284 vs 3.094 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 3 more results
5.442 vs 3.094 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.777 vs 3.094 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
6.756 vs 3.094 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
FACIT-Fatigue 9 vs 3.7 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 4 more results
7.9 vs 3.3 placebo score @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.3 vs 3.7 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
10.7 vs 3.7 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.6 vs 3.7 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
UC-related Surgery 0% (n=61) vs 0% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 0 Participants as posted
show 3 more results
0% (n=58) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 0 Participants as posted
2.1% (n=340) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 7 Participants as posted
1.6% (n=61) vs 0% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 1 Participants as posted

+ 8 further endpoints in the CSV export.

Crohn's Disease

Shared mechanism: IL-23 p19 · full Crohn's Disease pipeline

guselkumab · Tremfya

Marketed by Johnson & Johnson

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

QUASAR/GALAXI · Phase 3 · completed

Only IL-23i to beat ustekinumab head-to-head on endoscopy in a registrational trial — strong differentiator.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: March 2027 · NCT05347095 (registry estimate)

Reported efficacy

superior to ustekinumab on pooled endoscopic endpoints (met)

Result source: QUASAR/GALAXI

risankizumab · Skyrizi

Marketed by AbbVie and partners

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

NCT03104413 · Phase 3 · completed

Design meets the 'strong' test: randomized, double-blind, placebo-controlled, adequately powered (n~600), with a hard endoscopic co-primary endpoint (SES-CD response) plus CDAI clinical remission, and both primary endpoint comparisons were statistically significant in the favorable direction for both doses vs placebo.

Next expected readout: March 2027 · NCT06063967 (registry estimate)

Reported efficacy

US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12); US Specific: Percentage of Participants With Endoscopic Response (Week 12); Global Outside of US: Percentage of Participants With Clinical Remission (Week 12); Global Outside of US: Percentage of Participants With Endoscopic Response (Week 12): US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Induction Period 1) 19.8% (95% CI 14.1-25.5) vs Risankizumab 600mg (Induction Period 1) 42.0% (95% CI 34.9-49.0) vs Risankizumab 1200mg (Induction Period 1) 40.3% (95% CI 33.4-47.3); p=<0.001 (Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1)), p=< 0.001 (Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1)) (met)

Result source: NCT03104413

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointguselkumabrisankizumab
Clinical remission (induction)—Trial running · NCT0346641142% vs 19.8%+22.2 vs placebo600 mg · wk 12 · n 191NCT03104413
26 other results
  • 28.8% vs 11.2% 600 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 45.2% vs 24.6% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 43.5% vs 21.7% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 40.3% vs 19.8% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 34.2% vs 11.2% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 41.6% vs 24.6% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 41% vs 21.7% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 34.6% vs 19.3% 600 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 42% vs 19.8% 600 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 43.5% vs 21.7% 600mg · wk 12 · n 336 · Phase 3 · secondary NCT03105128
  • 45.2% vs 24.6% 600mg · wk 12 · n 336 · Phase 3 · secondary NCT03105128
  • 20.9% vs 11.2% 600 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 17.3% vs 8% 600 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 18.4% vs 10.3% 600mg · wk 4 · n 336 · Phase 3 · secondary NCT03105128
  • 21% vs 9.1% 600mg · wk 4 · n 336 · Phase 3 · secondary NCT03105128
  • 39.8% vs 19.3% 1200 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 40.3% vs 19.8% 1200 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 41% vs 21.7% 1200mg · wk 12 · n 339 · Phase 3 · secondary NCT03105128
  • 41.6% vs 24.6% 1200mg · wk 12 · n 339 · Phase 3 · secondary NCT03105128
  • 19.4% vs 11.2% 1200 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 18.3% vs 8% 1200 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 18.9% vs 10.3% 1200mg · wk 4 · n 339 · Phase 3 · secondary NCT03105128
  • 21.2% vs 9.1% 1200mg · wk 4 · n 339 · Phase 3 · secondary NCT03105128
  • 36.6% vs 15.4% 600 mg IV · wk 12 · n 41 · Phase 2 · primary NCT02031276
  • 28% vs 15.4% 200 + 600 mg IV · wk 12 · n 82 · Phase 2 · primary NCT02031276
  • 19.5% vs 15.4% 200 mg IV · wk 12 · n 41 · Phase 2 · primary NCT02031276
Endoscopic response (induction)—Trial running · NCT0346641128.8% vs 11.2%+17.6 vs placebo600 mg · wk 12 · n 191NCT03104413
10 other results
  • 34.6% vs 19.3% 600 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 40.3% vs 12% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 40.3% vs 12% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 34.2% vs 11.2% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 39.8% vs 19.3% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 32.1% vs 12% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 32.1% vs 12% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 36.6% vs 12.8% 600 mg IV · wk 12 · n 41 · Phase 2 · secondary NCT02031276
  • 31.7% vs 12.8% 200 + 600 mg IV · wk 12 · n 82 · Phase 2 · secondary NCT02031276
  • 26.8% vs 12.8% 200 mg IV · wk 12 · n 41 · Phase 2 · secondary NCT02031276
Clinical remission (maintenance)—Trial running · NCT03466411—Trial running · NCT06063967
Endoscopic response (maintenance)—Trial running · NCT03466411—Trial running · NCT06063967

Clinical remission (induction)

guselkumab
—Trial running · NCT03466411
risankizumab
42% vs 19.8%+22.2 vs placebo600 mg · wk 12 · n 191NCT03104413
26 other results
  • 28.8% vs 11.2% 600 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 45.2% vs 24.6% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 43.5% vs 21.7% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 40.3% vs 19.8% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 34.2% vs 11.2% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 41.6% vs 24.6% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 41% vs 21.7% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 34.6% vs 19.3% 600 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 42% vs 19.8% 600 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 43.5% vs 21.7% 600mg · wk 12 · n 336 · Phase 3 · secondary NCT03105128
  • 45.2% vs 24.6% 600mg · wk 12 · n 336 · Phase 3 · secondary NCT03105128
  • 20.9% vs 11.2% 600 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 17.3% vs 8% 600 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 18.4% vs 10.3% 600mg · wk 4 · n 336 · Phase 3 · secondary NCT03105128
  • 21% vs 9.1% 600mg · wk 4 · n 336 · Phase 3 · secondary NCT03105128
  • 39.8% vs 19.3% 1200 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 40.3% vs 19.8% 1200 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 41% vs 21.7% 1200mg · wk 12 · n 339 · Phase 3 · secondary NCT03105128
  • 41.6% vs 24.6% 1200mg · wk 12 · n 339 · Phase 3 · secondary NCT03105128
  • 19.4% vs 11.2% 1200 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 18.3% vs 8% 1200 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 18.9% vs 10.3% 1200mg · wk 4 · n 339 · Phase 3 · secondary NCT03105128
  • 21.2% vs 9.1% 1200mg · wk 4 · n 339 · Phase 3 · secondary NCT03105128
  • 36.6% vs 15.4% 600 mg IV · wk 12 · n 41 · Phase 2 · primary NCT02031276
  • 28% vs 15.4% 200 + 600 mg IV · wk 12 · n 82 · Phase 2 · primary NCT02031276
  • 19.5% vs 15.4% 200 mg IV · wk 12 · n 41 · Phase 2 · primary NCT02031276

Endoscopic response (induction)

guselkumab
—Trial running · NCT03466411
risankizumab
28.8% vs 11.2%+17.6 vs placebo600 mg · wk 12 · n 191NCT03104413
10 other results
  • 34.6% vs 19.3% 600 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 40.3% vs 12% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 40.3% vs 12% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 34.2% vs 11.2% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 39.8% vs 19.3% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 32.1% vs 12% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 32.1% vs 12% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 36.6% vs 12.8% 600 mg IV · wk 12 · n 41 · Phase 2 · secondary NCT02031276
  • 31.7% vs 12.8% 200 + 600 mg IV · wk 12 · n 82 · Phase 2 · secondary NCT02031276
  • 26.8% vs 12.8% 200 mg IV · wk 12 · n 41 · Phase 2 · secondary NCT02031276

Clinical remission (maintenance)

guselkumab
—Trial running · NCT03466411
risankizumab
—Trial running · NCT06063967

Endoscopic response (maintenance)

guselkumab
—Trial running · NCT03466411
risankizumab
—Trial running · NCT06063967
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. guselkumab: 3 of 4 rows · risankizumab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricguselkumabrisankizumab
Dropout rate
12.3%200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
show 7 more results
2%200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
5.4%200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
8.6%200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
11.5%200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
20.5%1200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
12.3%600 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
5.3%200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3
1.9%600 mga
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 16 more results
—360 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—180 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
2.9%1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—600mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—360mg SC
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—180mg SC
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—600 mg IV
NCT02513459 · Phase 2 · registry result, not featured evidence
—180 mg SC
NCT02513459 · Phase 2 · registry result, not featured evidence
—600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
—600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
—180 mg SC
NCT02031276 · Phase 2 · registry result, not featured evidence
—200 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
show 7 more results
—200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
—200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
—200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
—200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
—1200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
—600 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
—200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—600 mga
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 16 more results
—360 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—180 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—600mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—360mg SC
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—180mg SC
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—600 mg IV
NCT02513459 · Phase 2 · registry result, not featured evidence
—180 mg SC
NCT02513459 · Phase 2 · registry result, not featured evidence
—600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
—600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
—180 mg SC
NCT02031276 · Phase 2 · registry result, not featured evidence
—200 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
Serious AEs
8.2%200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
show 7 more results
4.1%200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
12.8%200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
9.9%200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
8.8%200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
6.8%1200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
6.8%600 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
7.9%200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3
4.9%600 mga
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 16 more results
4.8%360 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
4.9%180 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
4.4%1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
7.1%1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
7.2%600mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
4.4%360mg SC
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
4.5%180mg SC
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
3.8%1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
5.3%1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
6%1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
0%600 mg IV
NCT02513459 · Phase 2 · registry result, not featured evidence
35.4%180 mg SC
NCT02513459 · Phase 2 · registry result, not featured evidence
9.8%600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
10.9%600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
11.3%180 mg SC
NCT02031276 · Phase 2 · registry result, not featured evidence
24.4%200 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
200 mg IV q4w followed by 100 mg SC q8w
arthralgia 11% (placebo 7%)
nasopharyngitis 11% (placebo 9.3%)
crohn's disease 8.2% (placebo 11.6%)
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
show 7 more results
200 mg IV q4w followed by 200 mg SC q4w
covid-19 14.9% (placebo 0%)
headache 10.8% (placebo 9.3%)
arthralgia 9.5% (placebo 7%)
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
200 mg IV q4w followed by 100 mg SC q8w
covid-19 12.2% (placebo 0%)
upper respiratory tract infection 10.1% (placebo 4.7%)
arthralgia 9.5% (placebo 7%)
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
200 mg IV q4w followed by 200 mg SC q4w
covid-19 20.5% (placebo 0%)
upper respiratory tract infection 8.6% (placebo 4.7%)
arthralgia 7.3% (placebo 7%)
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
200 mg IV q4w followed by 100 mg SC q8w
covid-19 18.2% (placebo 0%)
upper respiratory tract infection 9.5% (placebo 4.7%)
crohn's disease 6.8% (placebo 11.6%)
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
1200 mg IV q4w followed by 200 mg SC q4w
nasopharyngitis 11% (placebo 9.3%)
headache 9.6% (placebo 9.3%)
arthralgia 5.5% (placebo 7%)
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
600 mg IV q4w followed by 200 mg SC q4w
headache 13.7% (placebo 9.3%)
nasopharyngitis 12.3% (placebo 9.3%)
anaemia 8.2% (placebo 2.3%)
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
200 mg
pyrexia 39.5%
headache 15.8%
nasopharyngitis 10.5%
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3
600 mga
headache 5.3% (placebo 5.3%)
arthralgia 3.9% (placebo 3.9%)
nasopharyngitis 3.9% (placebo 5.3%)
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 16 more results
360 mg
arthralgia 2.4% (placebo 3.9%)
headache 2.4% (placebo 5.3%)
nausea 2.4% (placebo 4.8%)
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
180 mg
arthralgia 4.9% (placebo 3.9%)
crohn's disease 2.4% (placebo 6.3%)
headache 2.4% (placebo 5.3%)
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
1200 mg
headache 4.9% (placebo 5.3%)
arthralgia 4.4% (placebo 3.9%)
nasopharyngitis 3.9% (placebo 5.3%)
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
1200 mg
headache 7.1% (placebo 5.3%)
nausea 7.1% (placebo 4.8%)
crohn's disease 4.8% (placebo 6.3%)
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
600mg IV
headache 6.4% (placebo 4.3%)
nasopharyngitis 5.9% (placebo 2.7%)
nausea 4.3% (placebo 5.4%)
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
360mg SC
headache 4.4% (placebo 4.3%)
anaemia 2.9% (placebo 2.7%)
crohn's disease 1.5% (placebo 5.4%)
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
180mg SC
crohn's disease 3% (placebo 5.4%)
headache 1.5% (placebo 4.3%)
nasopharyngitis 1.5% (placebo 2.7%)
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
1200mg IV
nasopharyngitis 5.9% (placebo 2.7%)
headache 5.4% (placebo 4.3%)
nausea 3.5% (placebo 5.4%)
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
1200mg IV
headache 6.6% (placebo 4.3%)
anaemia 5.3% (placebo 2.7%)
nausea 3.9% (placebo 5.4%)
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
1200mg IV
headache 3% (placebo 4.3%)
anaemia 1.5% (placebo 2.7%)
nasopharyngitis 1.5% (placebo 2.7%)
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
600 mg IV
abdominal pain upper 25%
ear pain 25%
haematochezia 25%
NCT02513459 · Phase 2 · registry result, not featured evidence
180 mg SC
nasopharyngitis 30.8%
gastroenteritis 23.1%
fatigue 20%
NCT02513459 · Phase 2 · registry result, not featured evidence
600 mg IV
arthralgia 19.5% (placebo 10.3%)
headache 12.2% (placebo 12.8%)
abdominal pain 9.8% (placebo 12.8%)
NCT02031276 · Phase 2 · registry result, not featured evidence
600 mg IV
abdominal pain 10.9% (placebo 12.8%)
nasopharyngitis 7.9% (placebo 7.7%)
arthralgia 6.9% (placebo 10.3%)
NCT02031276 · Phase 2 · registry result, not featured evidence
180 mg SC
nasopharyngitis 14.5% (placebo 7.7%)
arthralgia 9.7% (placebo 10.3%)
headache 9.7% (placebo 12.8%)
NCT02031276 · Phase 2 · registry result, not featured evidence
200 mg IV
nausea 22% (placebo 10.3%)
abdominal pain 14.6% (placebo 12.8%)
arthralgia 14.6% (placebo 10.3%)
NCT02031276 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 6 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

guselkumab

CDAI -159.8 vs -34.4 placebo score @ 12wk200 mg IV q4w followed by 100 mg SC q8w
absolute change · score
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
show 2 more results
-143.7 vs -34.4 placebo score @ 12wk1200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
-139.2 vs -34.4 placebo score @ 12wk600 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
Clinical Response W12 Clinical Remission W48 54.8% (n=146) vs 11.8% (n=76) placebo @ 48wk200 mg IV q4w followed by 200 mg SC q4w
responder rate · % of participants
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
show 3 more results
49% (n=143) vs 11.8% (n=76) placebo @ 48wk200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
48% (n=150) vs 12.5% (n=72) placebo @ 48wk200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
46.9% (n=143) vs 12.5% (n=72) placebo @ 48wk200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
Clinical Response W12 Endoscopic Response W48 38.4% (n=146) vs 5.3% (n=76) placebo @ 48wk200 mg IV q4w followed by 200 mg SC q4w
responder rate · % of participants
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
show 3 more results
39.2% (n=143) vs 5.3% (n=76) placebo @ 48wk200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
36% (n=150) vs 5.6% (n=72) placebo @ 48wk200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
33.6% (n=143) vs 5.6% (n=72) placebo @ 48wk200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
Clinical Response 52.6% (n=38) @ 4wk200 mg
responder rate · % of participants
No placebo or comparator arm
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 20 Participants as posted
show 11 more results
65.8% (n=38) @ 8wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 25 Participants as posted
78.9% (n=38) @ 12wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 30 Participants as posted
73.7% (n=38) @ 16wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 28 Participants as posted
73.7% (n=38) @ 20wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 28 Participants as posted
78.9% (n=38) @ 24wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 30 Participants as posted
76.3% (n=38) @ 28wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 29 Participants as posted
76.3% (n=38) @ 32wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 29 Participants as posted
76.3% (n=38) @ 36wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 29 Participants as posted
73.7% (n=38) @ 40wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 28 Participants as posted
76.3% (n=38) @ 44wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 29 Participants as posted
81.6% (n=38) @ 48wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 31 Participants as posted
Clinical Remission 44.7% (n=38) @ 4wk200 mg
responder rate · % of participants
No placebo or comparator arm
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 17 Participants as posted
show 11 more results
50% (n=38) @ 8wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 19 Participants as posted
60.5% (n=38) @ 12wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 23 Participants as posted
60.5% (n=38) @ 16wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 23 Participants as posted
57.9% (n=38) @ 20wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 22 Participants as posted
65.8% (n=38) @ 24wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 25 Participants as posted
65.8% (n=38) @ 28wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 25 Participants as posted
65.8% (n=38) @ 32wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 25 Participants as posted
68.4% (n=38) @ 36wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 26 Participants as posted
60.5% (n=38) @ 40wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 23 Participants as posted
65.8% (n=38) @ 44wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 25 Participants as posted
76.3% (n=38) @ 48wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 29 Participants as posted
PRO-2 Remission 15.8% (n=38) @ 4wk200 mg
responder rate · % of participants
No placebo or comparator arm
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 6 Participants as posted
show 11 more results
31.6% (n=38) @ 8wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 12 Participants as posted
42.1% (n=38) @ 12wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 16 Participants as posted
42.1% (n=38) @ 16wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 16 Participants as posted
50% (n=38) @ 20wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 19 Participants as posted
47.4% (n=38) @ 24wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 18 Participants as posted
55.3% (n=38) @ 28wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 21 Participants as posted
50% (n=38) @ 32wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 19 Participants as posted
52.6% (n=38) @ 36wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 20 Participants as posted
55.3% (n=38) @ 40wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 21 Participants as posted
60.5% (n=38) @ 44wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 23 Participants as posted
57.9% (n=38) @ 48wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 22 Participants as posted
SES-CD -6.4 score @ 48wk200 mg
absolute change · score
No placebo or comparator arm
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3

risankizumab

Clinical Remission 42% (n=191) vs 19.8% (n=187) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 26 more results
28.8% (n=191) vs 11.2% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
34.6% (n=191) vs 19.3% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
20.9% (n=191) vs 11.2% (n=187) placebo @ 4wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
42% (n=191) vs 19.8% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
17.3% (n=191) vs 8% (n=187) placebo @ 4wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
45.2% (n=336) vs 24.6% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
43.5% (n=336) vs 21.7% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
43.5% (n=336) vs 21.7% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
18.4% (n=336) vs 10.3% (n=175) placebo @ 4wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
45.2% (n=336) vs 24.6% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
21% (n=336) vs 9.1% (n=175) placebo @ 4wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
36.6% (n=41) vs 15.4% (n=39) placebo @ 12wk600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
28% (n=82) vs 15.4% (n=39) placebo @ 12wk200 + 600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
40.3% (n=191) vs 19.8% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
34.2% (n=191) vs 11.2% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
39.8% (n=191) vs 19.3% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
19.4% (n=191) vs 11.2% (n=187) placebo @ 4wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
40.3% (n=191) vs 19.8% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
18.3% (n=191) vs 8% (n=187) placebo @ 4wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
41.6% (n=339) vs 24.6% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
41% (n=339) vs 21.7% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
41% (n=339) vs 21.7% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
18.9% (n=339) vs 10.3% (n=175) placebo @ 4wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
41.6% (n=339) vs 24.6% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
21.2% (n=339) vs 9.1% (n=175) placebo @ 4wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
19.5% (n=41) vs 15.4% (n=39) placebo @ 12wk200 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
Endoscopic 28.8% (n=191) vs 11.2% (n=187) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 10 more results
34.6% (n=191) vs 19.3% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
40.3% (n=336) vs 12% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
40.3% (n=336) vs 12% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
36.6% (n=41) vs 12.8% (n=39) placebo @ 12wk600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
31.7% (n=82) vs 12.8% (n=39) placebo @ 12wk200 + 600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
34.2% (n=191) vs 11.2% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
39.8% (n=191) vs 19.3% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
32.1% (n=339) vs 12% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
32.1% (n=339) vs 12% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
26.8% (n=41) vs 12.8% (n=39) placebo @ 12wk200 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
CDAI 36.6% (n=191) vs 20.9% (n=187) placebo @ 4wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 15 more results
59.5% (n=191) vs 30% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
36.6% (n=191) vs 20.9% (n=187) placebo @ 4wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
59.5% (n=191) vs 30% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
40.8% (n=336) vs 25.2% (n=175) placebo @ 4wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
59.7% (n=336) vs 36.7% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
40.8% (n=336) vs 25.2% (n=175) placebo @ 4wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
59.7% (n=336) vs 36.7% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
32.5% (n=191) vs 20.9% (n=187) placebo @ 4wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
60.7% (n=191) vs 30% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
32.5% (n=191) vs 20.9% (n=187) placebo @ 4wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
60.7% (n=191) vs 30% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
37.2% (n=339) vs 25.2% (n=175) placebo @ 4wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
64.9% (n=339) vs 36.7% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
37.2% (n=339) vs 25.2% (n=175) placebo @ 4wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
64.9% (n=339) vs 36.7% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
CDAI Response and Endoscopic 20.5% (n=191) vs 5.3% (n=187) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 3 more results
30% (n=336) vs 5.7% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
23% (n=191) vs 5.3% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
23% (n=339) vs 5.7% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
Stool Frequency Remission 46.1% (n=191) vs 28.3% (n=187) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 3 more results
54.2% (n=336) vs 29.8% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
48.7% (n=191) vs 28.3% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
54% (n=339) vs 29.8% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
Abdominal Pain Remission 58.1% (n=191) vs 36.4% (n=187) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 3 more results
59.6% (n=336) vs 38.5% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
59.2% (n=191) vs 36.4% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
58.1% (n=339) vs 38.5% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
Endoscopic Remission 19.4% (n=191) vs 4.3% (n=187) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 10 more results
19.4% (n=191) vs 4.3% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
24.2% (n=336) vs 9.1% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
24.2% (n=336) vs 9.1% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
19.5% (n=41) vs 2.6% (n=39) placebo @ 12wk600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
14.6% (n=82) vs 2.6% (n=39) placebo @ 12wk200 + 600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
20.4% (n=191) vs 4.3% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
20.4% (n=191) vs 4.3% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
23.9% (n=339) vs 9.1% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
23.9% (n=339) vs 9.1% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
9.8% (n=41) vs 2.6% (n=39) placebo @ 12wk200 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
Enhanced Clinical 45% (n=191) vs 31.6% (n=187) placebo @ 4wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 15 more results
61.8% (n=191) vs 39.1% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
45% (n=191) vs 31.6% (n=187) placebo @ 4wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
61.8% (n=191) vs 39.1% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
46% (n=336) vs 31% (n=175) placebo @ 4wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
62.8% (n=336) vs 41.9% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
46% (n=336) vs 31% (n=175) placebo @ 4wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
62.8% (n=336) vs 41.9% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
38.7% (n=191) vs 31.6% (n=187) placebo @ 4wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
59.2% (n=191) vs 39.1% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
38.7% (n=191) vs 31.6% (n=187) placebo @ 4wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
59.2% (n=191) vs 39.1% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
43.4% (n=339) vs 31% (n=175) placebo @ 4wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
64.3% (n=339) vs 41.9% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
43.4% (n=339) vs 31% (n=175) placebo @ 4wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
64.3% (n=339) vs 41.9% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
Ulcer-Free Endoscopy 13.8% (n=190) vs 4.3% (n=186) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 7 more results
13.8% (n=190) vs 4.3% (n=186) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
21% (n=336) vs 7.6% (n=173) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
21% (n=336) vs 7.6% (n=173) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
15.4% (n=189) vs 4.3% (n=186) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
15.4% (n=189) vs 4.3% (n=186) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
16.4% (n=339) vs 7.6% (n=173) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
16.4% (n=338) vs 7.6% (n=173) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
EIM Resolution 29.5% (n=100) vs 23.7% (n=97) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 7 more results
29.5% (n=100) vs 23.7% (n=97) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
38.1% (n=140) vs 20.5% (n=64) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
38.1% (n=140) vs 20.5% (n=64) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
37.1% (n=97) vs 23.7% (n=97) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
37.1% (n=97) vs 23.7% (n=97) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
43.7% (n=158) vs 20.5% (n=64) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
43.7% (n=158) vs 20.5% (n=64) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
CD-Related Hospitalization 3.1% (n=191) vs 11.2% (n=187) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 7 more results
3.1% (n=191) vs 11.2% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
3.3% (n=339) vs 12% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
3.3% (n=336) vs 12% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
2.1% (n=191) vs 11.2% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
2.1% (n=191) vs 11.2% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
1.8% (n=339) vs 12% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
1.8% (n=339) vs 12% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
Draining Fistula Closure 7.1% (n=14) vs 13.3% (n=15) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 7 more results
7.1% (n=14) vs 13.3% (n=15) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
27.8% (n=18) vs 22.2% (n=9) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
27.8% (n=18) vs 22.2% (n=9) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
43.8% (n=16) vs 13.3% (n=15) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
43.8% (n=16) vs 13.3% (n=15) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
29.2% (n=24) vs 22.2% (n=9) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
29.2% (n=24) vs 22.2% (n=9) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3

+ 32 further endpoints in the CSV export.

Psoriatic Arthritis

Shared mechanism: IL-23 p19 · full Psoriatic Arthritis pipeline

guselkumab · Tremfya

Marketed by Johnson & Johnson

Approved in Psoriatic Arthritismonoclonal antibody
Reliable signal

NCT03162796 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial, and both guselkumab doses beat placebo on the week-24 ACR20 joint response (p<0.001). The protocol's sample-size calculation called for 360 patients, and 383 were enrolled.

Next expected readout: April 2027 · NCT04929210 (registry estimate)

Reported efficacy

Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (At Week 24): Group 1: Guselkumab 100 mg q8w 68.3 percentage of participants | Group 2: Guselkumab 100 mg q4w 66.6 percentage of participants | Group 3: Placebo Followed by Guselkumab 47 percentage of participants (met)

Result source: NCT04882098

risankizumab · Skyrizi

Marketed by AbbVie and partners

Approved in Psoriatic Arthritismonoclonal antibody
Reliable signal

NCT03675308 · Phase 3 · active, not recruiting

Randomized, double-blind, placebo-controlled trial in 964 patients with a validated clinical response measure (ACR20 at week 24) as the primary endpoint, which risankizumab met (57.3% vs 33.5%, p<0.001). The protocol and the published report state a power calculation for the ACR20 endpoint based on about 880 patients, and 964 were randomized.

Next expected readout: August 2029 · NCT06865105 (registry estimate)

Reported efficacy

Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24): Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24): Placebo 33.5 percentage of participants (95% CI 29.3 to 37.8) | Risankizumab 57.3 percentage of participants (95% CI 52.9 to 61.8) (met)

Result source: NCT03675308

Results for Psoriatic Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointguselkumabrisankizumab
ACR2052% vs 22.2%+29.8 vs placebo100 mg q8w · wk 24 · n 127NCT03162796
27 other results
  • 59.4% vs 22.2% 100 mg q4w · wk 24 · n 128 · Phase 3 · primary NCT03162796
  • 52% vs 25.4% 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • 60.2% vs 25.4% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 52% vs 25.4% 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • 60.2% vs 25.4% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 43.3% vs 27% 100 mg q8w · wk 12 · n 127 · Phase 3 · secondary NCT03162796
  • 53.1% vs 27% 100 mg q4w · wk 12 · n 128 · Phase 3 · secondary NCT03162796
  • 51.2% vs 30.2% 100 mg q8w · wk 20 · n 127 · Phase 3 · secondary NCT03162796
  • 62.5% vs 30.2% 100 mg q4w · wk 20 · n 128 · Phase 3 · secondary NCT03162796
  • 36.2% vs 18.3% 100 mg q8w · wk 8 · n 127 · Phase 3 · secondary NCT03162796
  • 39.1% vs 18.3% 100 mg q4w · wk 8 · n 128 · Phase 3 · secondary NCT03162796
  • 52% vs 22.2% 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • 59.4% vs 22.2% 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • 54.5% vs 27.2% 100 mg q8w · wk 24 · n 123 · Phase 3 · secondary NCT03162796
  • 60.8% vs 27.2% 100 mg q4w · wk 24 · n 125 · Phase 3 · secondary NCT03162796
  • 15.7% vs 7.9% 100 mg q8w · wk 4 · n 127 · Phase 3 · secondary NCT03162796
  • 20.3% vs 7.9% 100 mg q4w · wk 4 · n 128 · Phase 3 · secondary NCT03162796
  • 68.9% vs 50% 100 mg q8w · wk 28 · n 123 · Phase 3 · secondary NCT03162796
  • 74.4% vs 50% 100 mg q4w · wk 28 · n 125 · Phase 3 · secondary NCT03162796
  • 70.3% vs 56.9% 100 mg q8w · wk 36 · n 123 · Phase 3 · secondary NCT03162796
  • 71.1% vs 56.9% 100 mg q4w · wk 36 · n 125 · Phase 3 · secondary NCT03162796
  • 73.5% vs 61.7% 100 mg q8w · wk 44 · n 123 · Phase 3 · secondary NCT03162796
  • 72% vs 61.7% 100 mg q4w · wk 44 · n 125 · Phase 3 · secondary NCT03162796
  • 67.9% vs 68.3% 100 mg q8w · wk 52 · n 123 · Phase 3 · secondary NCT03162796
  • 75.8% vs 68.3% 100 mg q4w · wk 52 · n 125 · Phase 3 · secondary NCT03162796
  • 58% vs 18.4% wk 24 · n 100 · Phase 2 · primary NCT02319759
  • 60% vs 16.3% wk 16 · n 100 · Phase 2 · secondary NCT02319759
61.9% vs 35.7%+26.2 vs placebo150 mg weeks 0, 4, and 16 · wk 16 · n 42NCT02719171
5 other results
  • 59% vs 35.7% 150 mg weeks 0 and 12 · wk 16 · n 39 · Phase 2 · primary NCT02719171
  • 60.5% vs 35.7% 150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12 · wk 16 · n 81 · Phase 2 · primary NCT02719171
  • 57.1% vs 35.7% 150 mg every 4 weeks · wk 16 · n 42 · Phase 2 · primary NCT02719171
  • 59.5% vs 35.7% 150 mg every 4 weeks; 150 mg weeks 0, 4, 16 · wk 16 · n 84 · Phase 2 · primary NCT02719171
  • 65% vs 35.7% 75 mg week 0 · wk 16 · n 20 · Phase 2 · primary NCT02719171
ACR5022.8% vs 12.7%+10.1 vs placebo100 mg q8w · wk 16 · n 127NCT03162796
26 other results
  • 26.6% vs 12.7% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 22.8% vs 12.7% 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • 26.6% vs 12.7% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 20.5% vs 10.3% 100 mg q8w · wk 12 · n 127 · Phase 3 · secondary NCT03162796
  • 24.2% vs 10.3% 100 mg q4w · wk 12 · n 128 · Phase 3 · secondary NCT03162796
  • 29.1% vs 13.5% 100 mg q8w · wk 20 · n 127 · Phase 3 · secondary NCT03162796
  • 37.5% vs 13.5% 100 mg q4w · wk 20 · n 128 · Phase 3 · secondary NCT03162796
  • 29.9% vs 8.7% 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • 35.9% vs 8.7% 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • 7.9% vs 7.9% 100 mg q8w · wk 8 · n 127 · Phase 3 · secondary NCT03162796
  • 10.9% vs 7.9% 100 mg q4w · wk 8 · n 128 · Phase 3 · secondary NCT03162796
  • 29.9% vs 8.7% 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • 35.9% vs 8.7% 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • 30.9% vs 9.6% 100 mg q8w · wk 24 · n 123 · Phase 3 · secondary NCT03162796
  • 36.8% vs 9.6% 100 mg q4w · wk 24 · n 125 · Phase 3 · secondary NCT03162796
  • 1.6% vs 2.4% 100 mg q8w · wk 4 · n 127 · Phase 3 · secondary NCT03162796
  • 3.1% vs 2.4% 100 mg q4w · wk 4 · n 128 · Phase 3 · secondary NCT03162796
  • 42.6% vs 21.4% 100 mg q8w · wk 28 · n 123 · Phase 3 · secondary NCT03162796
  • 39.2% vs 21.4% 100 mg q4w · wk 28 · n 125 · Phase 3 · secondary NCT03162796
  • 47.1% vs 32.7% 100 mg q8w · wk 36 · n 123 · Phase 3 · secondary NCT03162796
  • 44.6% vs 32.7% 100 mg q4w · wk 36 · n 125 · Phase 3 · secondary NCT03162796
  • 51.3% vs 30.8% 100 mg q8w · wk 44 · n 123 · Phase 3 · secondary NCT03162796
  • 46% vs 30.8% 100 mg q4w · wk 44 · n 125 · Phase 3 · secondary NCT03162796
  • 43.4% vs 36.5% 100 mg q8w · wk 52 · n 123 · Phase 3 · secondary NCT03162796
  • 55.6% vs 36.5% 100 mg q4w · wk 52 · n 125 · Phase 3 · secondary NCT03162796
  • 34% vs 10.2% wk 24 · n 100 · Phase 2 · secondary NCT02319759
23.8% vs 11.9%+11.9 vs placebo150 mg weeks 0, 4, and 16 · wk 16 · n 42NCT02719171
5 other results
  • 38.5% vs 11.9% 150 mg weeks 0 and 12 · wk 16 · n 39 · Phase 2 · secondary NCT02719171
  • 30.9% vs 11.9% 150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12 · wk 16 · n 81 · Phase 2 · secondary NCT02719171
  • 23.8% vs 11.9% 150 mg every 4 weeks · wk 16 · n 42 · Phase 2 · secondary NCT02719171
  • 23.8% vs 11.9% 150 mg every 4 weeks; 150 mg weeks 0, 4, and 16 · wk 16 · n 84 · Phase 2 · secondary NCT02719171
  • 25% vs 11.9% 75 mg week 0 · wk 16 · n 20 · Phase 2 · secondary NCT02719171
PASI 7580% vs 84.8%−4.8 vs placebo100 mg q8w · wk 52 · n 82NCT03162796
8 other results
  • 94.3% vs 84.8% 100 mg q4w · wk 52 · n 88 · Phase 3 · secondary NCT03162796
  • 75.6% vs 14.1% 100 mg q8w · wk 24 · n 82 · Phase 3 · secondary NCT03162796
  • 86.5% vs 14.1% 100 mg q4w · wk 24 · n 89 · Phase 3 · secondary NCT03162796
  • 76.5% vs 20.6% 100 mg q8w · wk 24 · n 82 · Phase 3 · secondary NCT03162796
  • 87.5% vs 20.6% 100 mg q4w · wk 24 · n 88 · Phase 3 · secondary NCT03162796
  • 63.4% vs 20.5% 100 mg q8w · wk 16 · n 82 · Phase 3 · secondary NCT03162796
  • 73% vs 20.5% 100 mg q4w · wk 16 · n 89 · Phase 3 · secondary NCT03162796
  • 78.6% vs 12.5% wk 24 · n 98 · Phase 2 · secondary NCT02319759
—Not posted · NCT06624228
Minimal disease activity33.9% vs 31.1%+2.8 vs placebo100 mg q8w · wk 52 · n 123NCT03162796
9 other results
  • 40.3% vs 31.1% 100 mg q4w · wk 52 · n 125 · Phase 3 · secondary NCT03162796
  • 22.8% vs 11.1% 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • 30.5% vs 11.1% 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • 23.6% vs 12.3% 100 mg q8w · wk 24 · n 123 · Phase 3 · secondary NCT03162796
  • 31.2% vs 12.3% 100 mg q4w · wk 24 · n 125 · Phase 3 · secondary NCT03162796
  • 15.7% vs 7.1% 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • 18% vs 7.1% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 23% vs 2% wk 24 · n 100 · Phase 2 · secondary NCT02319759
  • 18% vs 0% wk 16 · n 100 · Phase 2 · secondary NCT02319759
—Not posted · NCT06624228
HAQ-DI, change-0.3 vs -0.1−0.1 vs placebo100 mg q8w · wk 16 · n 127NCT03162796
30 other results
  • -0.3 vs -0.1 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • -0.2 vs -0.1 100 mg q8w · wk 12 · n 127 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q4w · wk 12 · n 128 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q8w · wk 20 · n 127 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 100 mg q4w · wk 20 · n 128 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • -0.2 vs -0.1 100 mg q8w · wk 8 · n 127 · Phase 3 · secondary NCT03162796
  • -0.2 vs -0.1 100 mg q4w · wk 8 · n 128 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q8w · wk 24 · n 123 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 100 mg q4w · wk 24 · n 125 · Phase 3 · secondary NCT03162796
  • -0.1 vs 0.0 100 mg q8w · wk 4 · n 127 · Phase 3 · secondary NCT03162796
  • -0.1 vs 0.0 100 mg q4w · wk 4 · n 128 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.2 100 mg q8w · wk 28 · n 123 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.2 100 mg q4w · wk 28 · n 125 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.3 100 mg q8w · wk 36 · n 123 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.3 100 mg q4w · wk 36 · n 125 · Phase 3 · secondary NCT03162796
  • -0.5 vs -0.4 100 mg q8w · wk 44 · n 123 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.4 100 mg q4w · wk 44 · n 125 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.4 100 mg q8w · wk 52 · n 123 · Phase 3 · secondary NCT03162796
  • -0.5 vs -0.4 100 mg q4w · wk 52 · n 125 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 wk 16 · n 100 · Phase 2 · secondary NCT02319759
  • -0.3 vs -0.1 wk 12 · n 100 · Phase 2 · secondary NCT02319759
  • -0.4 vs -0.1 wk 20 · n 100 · Phase 2 · secondary NCT02319759
  • -0.4 vs -0.1 wk 24 · n 100 · Phase 2 · secondary NCT02319759
  • -0.3 vs -0.1 wk 8 · n 100 · Phase 2 · secondary NCT02319759
  • -0.4 vs -0.1 wk 24 · n 100 · Phase 2 · secondary NCT02319759
  • -0.2 vs -0.0 wk 4 · n 100 · Phase 2 · secondary NCT02319759
-0.2 vs -0.1−0.1 vs placebo150 mg weeks 0, 4, and 16 · wk 16 · n 40NCT02719171
5 other results
  • -0.2 vs -0.1 150 mg weeks 0 and 12 · wk 16 · n 38 · Phase 2 · secondary NCT02719171
  • -0.2 vs -0.1 150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12 · wk 16 · n 78 · Phase 2 · secondary NCT02719171
  • -0.2 vs -0.1 150 mg every 4 weeks · wk 16 · n 39 · Phase 2 · secondary NCT02719171
  • -0.2 vs -0.1 150 mg every 4 weeks; 150 mg weeks 0, 4, and 16 · wk 16 · n 79 · Phase 2 · secondary NCT02719171
  • -0.1 vs -0.1 75 mg week 0 · wk 16 · n 18 · Phase 2 · secondary NCT02719171

ACR20

guselkumab
52% vs 22.2%+29.8 vs placebo100 mg q8w · wk 24 · n 127NCT03162796
27 other results
  • 59.4% vs 22.2% 100 mg q4w · wk 24 · n 128 · Phase 3 · primary NCT03162796
  • 52% vs 25.4% 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • 60.2% vs 25.4% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 52% vs 25.4% 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • 60.2% vs 25.4% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 43.3% vs 27% 100 mg q8w · wk 12 · n 127 · Phase 3 · secondary NCT03162796
  • 53.1% vs 27% 100 mg q4w · wk 12 · n 128 · Phase 3 · secondary NCT03162796
  • 51.2% vs 30.2% 100 mg q8w · wk 20 · n 127 · Phase 3 · secondary NCT03162796
  • 62.5% vs 30.2% 100 mg q4w · wk 20 · n 128 · Phase 3 · secondary NCT03162796
  • 36.2% vs 18.3% 100 mg q8w · wk 8 · n 127 · Phase 3 · secondary NCT03162796
  • 39.1% vs 18.3% 100 mg q4w · wk 8 · n 128 · Phase 3 · secondary NCT03162796
  • 52% vs 22.2% 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • 59.4% vs 22.2% 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • 54.5% vs 27.2% 100 mg q8w · wk 24 · n 123 · Phase 3 · secondary NCT03162796
  • 60.8% vs 27.2% 100 mg q4w · wk 24 · n 125 · Phase 3 · secondary NCT03162796
  • 15.7% vs 7.9% 100 mg q8w · wk 4 · n 127 · Phase 3 · secondary NCT03162796
  • 20.3% vs 7.9% 100 mg q4w · wk 4 · n 128 · Phase 3 · secondary NCT03162796
  • 68.9% vs 50% 100 mg q8w · wk 28 · n 123 · Phase 3 · secondary NCT03162796
  • 74.4% vs 50% 100 mg q4w · wk 28 · n 125 · Phase 3 · secondary NCT03162796
  • 70.3% vs 56.9% 100 mg q8w · wk 36 · n 123 · Phase 3 · secondary NCT03162796
  • 71.1% vs 56.9% 100 mg q4w · wk 36 · n 125 · Phase 3 · secondary NCT03162796
  • 73.5% vs 61.7% 100 mg q8w · wk 44 · n 123 · Phase 3 · secondary NCT03162796
  • 72% vs 61.7% 100 mg q4w · wk 44 · n 125 · Phase 3 · secondary NCT03162796
  • 67.9% vs 68.3% 100 mg q8w · wk 52 · n 123 · Phase 3 · secondary NCT03162796
  • 75.8% vs 68.3% 100 mg q4w · wk 52 · n 125 · Phase 3 · secondary NCT03162796
  • 58% vs 18.4% wk 24 · n 100 · Phase 2 · primary NCT02319759
  • 60% vs 16.3% wk 16 · n 100 · Phase 2 · secondary NCT02319759
risankizumab
61.9% vs 35.7%+26.2 vs placebo150 mg weeks 0, 4, and 16 · wk 16 · n 42NCT02719171
5 other results
  • 59% vs 35.7% 150 mg weeks 0 and 12 · wk 16 · n 39 · Phase 2 · primary NCT02719171
  • 60.5% vs 35.7% 150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12 · wk 16 · n 81 · Phase 2 · primary NCT02719171
  • 57.1% vs 35.7% 150 mg every 4 weeks · wk 16 · n 42 · Phase 2 · primary NCT02719171
  • 59.5% vs 35.7% 150 mg every 4 weeks; 150 mg weeks 0, 4, 16 · wk 16 · n 84 · Phase 2 · primary NCT02719171
  • 65% vs 35.7% 75 mg week 0 · wk 16 · n 20 · Phase 2 · primary NCT02719171

ACR50

guselkumab
22.8% vs 12.7%+10.1 vs placebo100 mg q8w · wk 16 · n 127NCT03162796
26 other results
  • 26.6% vs 12.7% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 22.8% vs 12.7% 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • 26.6% vs 12.7% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 20.5% vs 10.3% 100 mg q8w · wk 12 · n 127 · Phase 3 · secondary NCT03162796
  • 24.2% vs 10.3% 100 mg q4w · wk 12 · n 128 · Phase 3 · secondary NCT03162796
  • 29.1% vs 13.5% 100 mg q8w · wk 20 · n 127 · Phase 3 · secondary NCT03162796
  • 37.5% vs 13.5% 100 mg q4w · wk 20 · n 128 · Phase 3 · secondary NCT03162796
  • 29.9% vs 8.7% 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • 35.9% vs 8.7% 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • 7.9% vs 7.9% 100 mg q8w · wk 8 · n 127 · Phase 3 · secondary NCT03162796
  • 10.9% vs 7.9% 100 mg q4w · wk 8 · n 128 · Phase 3 · secondary NCT03162796
  • 29.9% vs 8.7% 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • 35.9% vs 8.7% 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • 30.9% vs 9.6% 100 mg q8w · wk 24 · n 123 · Phase 3 · secondary NCT03162796
  • 36.8% vs 9.6% 100 mg q4w · wk 24 · n 125 · Phase 3 · secondary NCT03162796
  • 1.6% vs 2.4% 100 mg q8w · wk 4 · n 127 · Phase 3 · secondary NCT03162796
  • 3.1% vs 2.4% 100 mg q4w · wk 4 · n 128 · Phase 3 · secondary NCT03162796
  • 42.6% vs 21.4% 100 mg q8w · wk 28 · n 123 · Phase 3 · secondary NCT03162796
  • 39.2% vs 21.4% 100 mg q4w · wk 28 · n 125 · Phase 3 · secondary NCT03162796
  • 47.1% vs 32.7% 100 mg q8w · wk 36 · n 123 · Phase 3 · secondary NCT03162796
  • 44.6% vs 32.7% 100 mg q4w · wk 36 · n 125 · Phase 3 · secondary NCT03162796
  • 51.3% vs 30.8% 100 mg q8w · wk 44 · n 123 · Phase 3 · secondary NCT03162796
  • 46% vs 30.8% 100 mg q4w · wk 44 · n 125 · Phase 3 · secondary NCT03162796
  • 43.4% vs 36.5% 100 mg q8w · wk 52 · n 123 · Phase 3 · secondary NCT03162796
  • 55.6% vs 36.5% 100 mg q4w · wk 52 · n 125 · Phase 3 · secondary NCT03162796
  • 34% vs 10.2% wk 24 · n 100 · Phase 2 · secondary NCT02319759
risankizumab
23.8% vs 11.9%+11.9 vs placebo150 mg weeks 0, 4, and 16 · wk 16 · n 42NCT02719171
5 other results
  • 38.5% vs 11.9% 150 mg weeks 0 and 12 · wk 16 · n 39 · Phase 2 · secondary NCT02719171
  • 30.9% vs 11.9% 150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12 · wk 16 · n 81 · Phase 2 · secondary NCT02719171
  • 23.8% vs 11.9% 150 mg every 4 weeks · wk 16 · n 42 · Phase 2 · secondary NCT02719171
  • 23.8% vs 11.9% 150 mg every 4 weeks; 150 mg weeks 0, 4, and 16 · wk 16 · n 84 · Phase 2 · secondary NCT02719171
  • 25% vs 11.9% 75 mg week 0 · wk 16 · n 20 · Phase 2 · secondary NCT02719171

PASI 75

guselkumab
80% vs 84.8%−4.8 vs placebo100 mg q8w · wk 52 · n 82NCT03162796
8 other results
  • 94.3% vs 84.8% 100 mg q4w · wk 52 · n 88 · Phase 3 · secondary NCT03162796
  • 75.6% vs 14.1% 100 mg q8w · wk 24 · n 82 · Phase 3 · secondary NCT03162796
  • 86.5% vs 14.1% 100 mg q4w · wk 24 · n 89 · Phase 3 · secondary NCT03162796
  • 76.5% vs 20.6% 100 mg q8w · wk 24 · n 82 · Phase 3 · secondary NCT03162796
  • 87.5% vs 20.6% 100 mg q4w · wk 24 · n 88 · Phase 3 · secondary NCT03162796
  • 63.4% vs 20.5% 100 mg q8w · wk 16 · n 82 · Phase 3 · secondary NCT03162796
  • 73% vs 20.5% 100 mg q4w · wk 16 · n 89 · Phase 3 · secondary NCT03162796
  • 78.6% vs 12.5% wk 24 · n 98 · Phase 2 · secondary NCT02319759
risankizumab
—Not posted · NCT06624228

Minimal disease activity

guselkumab
33.9% vs 31.1%+2.8 vs placebo100 mg q8w · wk 52 · n 123NCT03162796
9 other results
  • 40.3% vs 31.1% 100 mg q4w · wk 52 · n 125 · Phase 3 · secondary NCT03162796
  • 22.8% vs 11.1% 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • 30.5% vs 11.1% 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • 23.6% vs 12.3% 100 mg q8w · wk 24 · n 123 · Phase 3 · secondary NCT03162796
  • 31.2% vs 12.3% 100 mg q4w · wk 24 · n 125 · Phase 3 · secondary NCT03162796
  • 15.7% vs 7.1% 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • 18% vs 7.1% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 23% vs 2% wk 24 · n 100 · Phase 2 · secondary NCT02319759
  • 18% vs 0% wk 16 · n 100 · Phase 2 · secondary NCT02319759
risankizumab
—Not posted · NCT06624228

HAQ-DI, change

guselkumab
-0.3 vs -0.1−0.1 vs placebo100 mg q8w · wk 16 · n 127NCT03162796
30 other results
  • -0.3 vs -0.1 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • -0.2 vs -0.1 100 mg q8w · wk 12 · n 127 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q4w · wk 12 · n 128 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q8w · wk 20 · n 127 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 100 mg q4w · wk 20 · n 128 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • -0.2 vs -0.1 100 mg q8w · wk 8 · n 127 · Phase 3 · secondary NCT03162796
  • -0.2 vs -0.1 100 mg q4w · wk 8 · n 128 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q8w · wk 24 · n 123 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 100 mg q4w · wk 24 · n 125 · Phase 3 · secondary NCT03162796
  • -0.1 vs 0.0 100 mg q8w · wk 4 · n 127 · Phase 3 · secondary NCT03162796
  • -0.1 vs 0.0 100 mg q4w · wk 4 · n 128 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.2 100 mg q8w · wk 28 · n 123 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.2 100 mg q4w · wk 28 · n 125 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.3 100 mg q8w · wk 36 · n 123 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.3 100 mg q4w · wk 36 · n 125 · Phase 3 · secondary NCT03162796
  • -0.5 vs -0.4 100 mg q8w · wk 44 · n 123 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.4 100 mg q4w · wk 44 · n 125 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.4 100 mg q8w · wk 52 · n 123 · Phase 3 · secondary NCT03162796
  • -0.5 vs -0.4 100 mg q4w · wk 52 · n 125 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 wk 16 · n 100 · Phase 2 · secondary NCT02319759
  • -0.3 vs -0.1 wk 12 · n 100 · Phase 2 · secondary NCT02319759
  • -0.4 vs -0.1 wk 20 · n 100 · Phase 2 · secondary NCT02319759
  • -0.4 vs -0.1 wk 24 · n 100 · Phase 2 · secondary NCT02319759
  • -0.3 vs -0.1 wk 8 · n 100 · Phase 2 · secondary NCT02319759
  • -0.4 vs -0.1 wk 24 · n 100 · Phase 2 · secondary NCT02319759
  • -0.2 vs -0.0 wk 4 · n 100 · Phase 2 · secondary NCT02319759
risankizumab
-0.2 vs -0.1−0.1 vs placebo150 mg weeks 0, 4, and 16 · wk 16 · n 40NCT02719171
5 other results
  • -0.2 vs -0.1 150 mg weeks 0 and 12 · wk 16 · n 38 · Phase 2 · secondary NCT02719171
  • -0.2 vs -0.1 150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12 · wk 16 · n 78 · Phase 2 · secondary NCT02719171
  • -0.2 vs -0.1 150 mg every 4 weeks · wk 16 · n 39 · Phase 2 · secondary NCT02719171
  • -0.2 vs -0.1 150 mg every 4 weeks; 150 mg weeks 0, 4, and 16 · wk 16 · n 79 · Phase 2 · secondary NCT02719171
  • -0.1 vs -0.1 75 mg week 0 · wk 16 · n 18 · Phase 2 · secondary NCT02719171
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety

Coverage. guselkumab: 14 of 14 rows · risankizumab: 14 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricguselkumab
Rows use multiple source trials
risankizumab
Rows use multiple source trials
ACR20
responder rate · % of participants
No placebo or comparator arm
75.9% (n=234) @ 52wk100 mg q4wa,b,c,d
NCT03158285 · Phase 3
show 3 more doses
77% (n=227) @ 52wk100 mg q4w
NCT03158285 · Phase 3
79.1% (n=240) @ 52wk100 mg q8w
NCT03158285 · Phase 3
78.9% (n=232) @ 52wk100 mg q8w
NCT03158285 · Phase 3
75.2% (n=101) @ 52wkb,c,d
NCT02986373 · Phase 2 · registry result, not featured evidence
ACR70
responder rate · % of participants
7.8% (n=128) vs 5.6% (n=126) placebo @ 16wk100 mg q4wa,b,c,d
NCT03162796 · Phase 3
show 1 more dose
7.9% (n=127) vs 5.6% (n=126) placebo @ 16wk100 mg q8w
NCT03162796 · Phase 3
25.6% (n=39) vs 0% (n=42) placebo @ 16wk150 mg weeks 0 and 12a,b,c,d
NCT02719171 · Phase 2 · registry result, not featured evidence
show 5 more doses
7.1% (n=42) vs 0% (n=42) placebo @ 16wk150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
16% (n=81) vs 0% (n=42) placebo @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
14.3% (n=42) vs 0% (n=42) placebo @ 16wk150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
10.7% (n=84) vs 0% (n=42) placebo @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
15% (n=20) vs 0% (n=42) placebo @ 16wk75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
HAQ-DI
absolute change · score
No placebo or comparator arm
-0.5082 score @ 52wk100 mg q4wa,b,c,d
NCT03158285 · Phase 3
show 3 more doses
-0.5111 score @ 52wk100 mg q4w
NCT03158285 · Phase 3
-0.4824 score @ 52wk100 mg q8w
NCT03158285 · Phase 3
-0.4801 score @ 52wk100 mg q8w
NCT03158285 · Phase 3
-0.318 score @ 52wkb,c,d
NCT02986373 · Phase 2 · registry result, not featured evidence
Modified Sharp
absolute change · score
No placebo or comparator arm
0.29 score @ 24wk100 mg q4wa,b,c,d
NCT03158285 · Phase 3
show 1 more dose
0.52 score @ 24wk100 mg q8w
NCT03158285 · Phase 3
0.12 score @ 24wka,b,c,d
NCT02986373 · Phase 2 · registry result, not featured evidence
show 1 more dose
0.38 score @ 24wk
NCT02986373 · Phase 2 · registry result, not featured evidence
PASI 90
responder rate · % of participants
52.8% (n=89) vs 10.3% (n=78) placebo @ 16wk100 mg q4wa,b,c,d
NCT03162796 · Phase 3
show 1 more dose
45.1% (n=82) vs 10.3% (n=78) placebo @ 16wk100 mg q8w
NCT03162796 · Phase 3
52.2% (n=23) vs 9.5% (n=21) placebo @ 16wk150 mg weeks 0 and 12a,b,c,d
NCT02719171 · Phase 2 · registry result, not featured evidence
show 5 more doses
66.7% (n=18) vs 9.5% (n=21) placebo @ 16wk150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
58.5% (n=41) vs 9.5% (n=21) placebo @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
58.3% (n=12) vs 9.5% (n=21) placebo @ 16wk150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
63.3% (n=30) vs 9.5% (n=21) placebo @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
55.6% (n=9) vs 9.5% (n=21) placebo @ 16wk75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
SF-36 MCS
absolute change · score
3.04 vs 2.25 placebo score @ 16wk100 mg q4wa,b,c,d
NCT03162796 · Phase 3
show 1 more dose
2.61 vs 2.25 placebo score @ 16wk100 mg q8w
NCT03162796 · Phase 3
2.84 vs 0.48 placebo score @ 16wk150 mg weeks 0 and 12a,b,c,d
NCT02719171 · Phase 2 · registry result, not featured evidence
show 5 more doses
2.26 vs 0.48 placebo score @ 16wk150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
2.29 vs 0.48 placebo score @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-0.36 vs 0.48 placebo score @ 16wk150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
1.31 vs 0.48 placebo score @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
-1.08 vs 0.48 placebo score @ 16wk75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
SF-36 MCS
absolute change · score
No placebo or comparator arm
4.076 score @ 52wk100 mg q4wa,b,c,d
NCT03158285 · Phase 3
show 3 more doses
4.127 score @ 52wk100 mg q4w
NCT03158285 · Phase 3
4.465 score @ 52wk100 mg q8w
NCT03158285 · Phase 3
4.54 score @ 52wk100 mg q8w
NCT03158285 · Phase 3
4.33 score @ 52wkb,c,d
NCT02986373 · Phase 2 · registry result, not featured evidence
SF-36 PCS
absolute change · score
6.72 vs 2.5 placebo score @ 16wk100 mg q4wa,b,c,d
NCT03162796 · Phase 3
show 1 more dose
5.26 vs 2.5 placebo score @ 16wk100 mg q8w
NCT03162796 · Phase 3
3.1 vs 1.93 placebo score @ 16wk150 mg weeks 0 and 12a,b,c,d
NCT02719171 · Phase 2 · registry result, not featured evidence
show 5 more doses
3.5 vs 1.93 placebo score @ 16wk150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
3.32 vs 1.93 placebo score @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
3.87 vs 1.93 placebo score @ 16wk150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
3.8 vs 1.93 placebo score @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
7.42 vs 1.93 placebo score @ 16wk75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
SF-36 PCS
absolute change · score
No placebo or comparator arm
8.96 score @ 52wk100 mg q4wa,b,c,d
NCT03158285 · Phase 3
show 3 more doses
9.023 score @ 52wk100 mg q4w
NCT03158285 · Phase 3
9.511 score @ 52wk100 mg q8w
NCT03158285 · Phase 3
9.438 score @ 52wk100 mg q8w
NCT03158285 · Phase 3
4.47 score @ 52wkb,c,d
NCT02986373 · Phase 2 · registry result, not featured evidence
SPARCC Enthesitis Index
absolute change · score
-4 vs -3.9 placebo score @ 52wk100 mg q4wa,b,c,d,e
NCT03162796 · Phase 3
show 1 more dose
-4.1 vs -3.9 placebo score @ 52wk100 mg q8w
NCT03162796 · Phase 3
-1.8 vs -1.1 placebo score @ 16wk150 mg weeks 0 and 12a,b,c,d,e
NCT02719171 · Phase 2 · registry result, not featured evidence
show 5 more doses
-2.4 vs -1.1 placebo score @ 16wk150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
-2.1 vs -1.1 placebo score @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-1.4 vs -1.1 placebo score @ 16wk150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
-1.7 vs -1.1 placebo score @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
-3.7 vs -1.1 placebo score @ 16wk75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
Dropout rate
2.3%100 mg q4wf
NCT03162796 · Phase 3
show 13 more results
—100 mg q4w
NCT03162796 · Phase 3
—100 mg q4w
NCT03162796 · Phase 3
3.1%100 mg q8w
NCT03162796 · Phase 3
—100 mg q8w
NCT03162796 · Phase 3
—100 mg q8w
NCT03162796 · Phase 3
3.7%100 mg q4w
NCT03158285 · Phase 3
—100 mg q4w
NCT03158285 · Phase 3
—100 mg q4w
NCT03158285 · Phase 3
3.2%100 mg q8w
NCT03158285 · Phase 3
—100 mg q8w
NCT03158285 · Phase 3
—100 mg q8w
NCT03158285 · Phase 3
1%Guselkumab (Week 0 to Week 56)
NCT02319759 · Phase 2 · registry result, not featured evidence
—Placebo to Guselkumab (Week 24 to
NCT02319759 · Phase 2 · registry result, not featured evidence
—150 mgf
NCT03671148 · Phase 3
show 5 more results
26.9%
NCT02986373 · Phase 2 · registry result, not featured evidence
5.1%150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
7.1%150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
9.5%150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
10%75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0.8%100 mg q4wf
NCT03162796 · Phase 3
show 13 more results
—100 mg q4w
NCT03162796 · Phase 3
—100 mg q4w
NCT03162796 · Phase 3
2.4%100 mg q8w
NCT03162796 · Phase 3
—100 mg q8w
NCT03162796 · Phase 3
—100 mg q8w
NCT03162796 · Phase 3
2.4%100 mg q4w
NCT03158285 · Phase 3
—100 mg q4w
NCT03158285 · Phase 3
—100 mg q4w
NCT03158285 · Phase 3
0.8%100 mg q8w
NCT03158285 · Phase 3
—100 mg q8w
NCT03158285 · Phase 3
—100 mg q8w
NCT03158285 · Phase 3
—Guselkumab (Week 0 to Week 56)
NCT02319759 · Phase 2 · registry result, not featured evidence
—Placebo to Guselkumab (Week 24 to
NCT02319759 · Phase 2 · registry result, not featured evidence
—150 mgf
NCT03671148 · Phase 3
show 5 more results
2.8%
NCT02986373 · Phase 2 · registry result, not featured evidence
0%150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
0%150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
4.8%150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
10%75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
Serious AEs
—100 mg q4wf
NCT03162796 · Phase 3
show 13 more results
0%100 mg q4w
NCT03162796 · Phase 3
3.1%100 mg q4w
NCT03162796 · Phase 3
—100 mg q8w
NCT03162796 · Phase 3
3.1%100 mg q8w
NCT03162796 · Phase 3
6.3%100 mg q8w
NCT03162796 · Phase 3
—100 mg q4w
NCT03158285 · Phase 3
3.3%100 mg q4w
NCT03158285 · Phase 3
9%100 mg q4w
NCT03158285 · Phase 3
—100 mg q8w
NCT03158285 · Phase 3
1.2%100 mg q8w
NCT03158285 · Phase 3
8.9%100 mg q8w
NCT03158285 · Phase 3
6%Guselkumab (Week 0 to Week 56)
NCT02319759 · Phase 2 · registry result, not featured evidence
0%Placebo to Guselkumab (Week 24 to
NCT02319759 · Phase 2 · registry result, not featured evidence
4%150 mgf
NCT03671148 · Phase 3
show 5 more results
3.4%
NCT02986373 · Phase 2 · registry result, not featured evidence
5.1%150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
0%150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
7.1%150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
15%75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
100 mg q4wf
upper respiratory tract infection 8.6% (placebo 6.3%)
nasopharyngitis 5.5% (placebo 6.3%)
enthesopathy 4.7% (placebo 4.8%)
NCT03162796 · Phase 3
show 9 more results
100 mg q4w
upper respiratory tract infection 12.5% (placebo 6.3%)
nasopharyngitis 10.9% (placebo 6.3%)
alanine aminotransferase increased 7% (placebo 2.4%)
NCT03162796 · Phase 3
100 mg q8w
nasopharyngitis 12.6% (placebo 6.3%)
aspartate aminotransferase increased 7.1% (placebo 2.4%)
alanine aminotransferase increased 6.3% (placebo 2.4%)
NCT03162796 · Phase 3
100 mg q8w
nasopharyngitis 16.5% (placebo 6.3%)
aspartate aminotransferase increased 8.7% (placebo 2.4%)
upper respiratory tract infection 7.9% (placebo 6.3%)
NCT03162796 · Phase 3
100 mg q4w
alanine aminotransferase increased 9% (placebo 4.5%)
upper respiratory tract infection 5.3% (placebo 3.3%)
nasopharyngitis 4.9% (placebo 3.7%)
NCT03158285 · Phase 3
100 mg q4w
alanine aminotransferase increased 12.7% (placebo 4.5%)
aspartate aminotransferase increased 9.4% (placebo 2.4%)
nasopharyngitis 8.6% (placebo 3.7%)
NCT03158285 · Phase 3
100 mg q8w
alanine aminotransferase increased 6% (placebo 4.5%)
aspartate aminotransferase increased 5.6% (placebo 2.4%)
nasopharyngitis 4% (placebo 3.7%)
NCT03158285 · Phase 3
100 mg q8w
alanine aminotransferase increased 11.7% (placebo 4.5%)
nasopharyngitis 10.1% (placebo 3.7%)
upper respiratory tract infection 9.7% (placebo 3.3%)
NCT03158285 · Phase 3
nasopharyngitis 10% (placebo 10.2%)
leukopenia 5% (placebo 0%)
alanine aminotransferase increased 4% (placebo 2%)
NCT02319759 · Phase 2 · registry result, not featured evidence
alanine aminotransferase increased 6.9% (placebo 2%)
aspartate aminotransferase increased 6.9% (placebo 0%)
leukopenia 3.4% (placebo 0%)
NCT02319759 · Phase 2 · registry result, not featured evidence
150 mgf
upper respiratory tract infection 7.6% (placebo 5%)
NCT03671148 · Phase 3
show 5 more results
viral upper respiratory tract infection 11%
NCT02986373 · Phase 2 · registry result, not featured evidence
150 mg weeks 0 and 12
viral upper respiratory tract infection 23.1% (placebo 4.8%)
headache 7.7% (placebo 7.1%)
abdominal pain 5.1% (placebo 2.4%)
NCT02719171 · Phase 2 · registry result, not featured evidence
150 mg weeks 0, 4, and 16
viral upper respiratory tract infection 11.9% (placebo 4.8%)
upper respiratory tract infection 7.1% (placebo 11.9%)
back pain 4.8% (placebo 2.4%)
NCT02719171 · Phase 2 · registry result, not featured evidence
150 mg every 4 weeks
viral upper respiratory tract infection 16.7% (placebo 4.8%)
cough 7.1% (placebo 4.8%)
fatigue 7.1% (placebo 0%)
NCT02719171 · Phase 2 · registry result, not featured evidence
75 mg week 0
viral upper respiratory tract infection 20% (placebo 4.8%)
abdominal discomfort 5% (placebo 0%)
alanine aminotransferase increased 5% (placebo 2.4%)
NCT02719171 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 16 weeks versus 52 weeks.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

guselkumab

IGA 0/1 57.3% (n=82) vs 15.4% (n=78) placebo @ 24wk100 mg q8w
responder rate · % of participants
NCT03162796 · Phase 3
show 5 more results
75.3% (n=89) vs 15.4% (n=78) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
38.3% (n=82) vs 8.8% (n=68) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
54.5% (n=88) vs 8.8% (n=68) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
53.3% (n=82) vs 66.2% (n=68) placebo @ 52wk100 mg q8w
NCT03162796 · Phase 3
67% (n=88) vs 66.2% (n=68) placebo @ 52wk100 mg q4w
NCT03162796 · Phase 3
DAS28-CRP -1.43 vs -0.7 placebo score @ 24wk100 mg q8w
absolute change · score
NCT03162796 · Phase 3
show 23 more results
-1.61 vs -0.7 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-0.53 vs -0.35 placebo score @ 4wk100 mg q8w
NCT03162796 · Phase 3
-0.56 vs -0.35 placebo score @ 4wk100 mg q4w
NCT03162796 · Phase 3
-0.83 vs -0.55 placebo score @ 8wk100 mg q8w
NCT03162796 · Phase 3
-0.88 vs -0.55 placebo score @ 8wk100 mg q4w
NCT03162796 · Phase 3
-1.16 vs -0.63 placebo score @ 12wk100 mg q8w
NCT03162796 · Phase 3
-1.23 vs -0.63 placebo score @ 12wk100 mg q4w
NCT03162796 · Phase 3
-1.19 vs -0.64 placebo score @ 16wk100 mg q8w
NCT03162796 · Phase 3
-1.38 vs -0.64 placebo score @ 16wk100 mg q4w
NCT03162796 · Phase 3
-1.38 vs -0.8 placebo score @ 20wk100 mg q8w
NCT03162796 · Phase 3
-1.56 vs -0.8 placebo score @ 20wk100 mg q4w
NCT03162796 · Phase 3
-1.43 vs -0.7 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
-1.61 vs -0.7 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-1.49 vs -0.84 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
-1.57 vs -0.84 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-1.71 vs -1.33 placebo score @ 28wk100 mg q8w
NCT03162796 · Phase 3
-1.67 vs -1.33 placebo score @ 28wk100 mg q4w
NCT03162796 · Phase 3
-1.96 vs -1.6 placebo score @ 36wk100 mg q8w
NCT03162796 · Phase 3
-1.78 vs -1.6 placebo score @ 36wk100 mg q4w
NCT03162796 · Phase 3
-1.96 vs -1.69 placebo score @ 44wk100 mg q8w
NCT03162796 · Phase 3
-1.92 vs -1.69 placebo score @ 44wk100 mg q4w
NCT03162796 · Phase 3
-2.03 vs -1.84 placebo score @ 52wk100 mg q8w
NCT03162796 · Phase 3
-1.99 vs -1.84 placebo score @ 52wk100 mg q4w
NCT03162796 · Phase 3
Enthesitis Resolution 40.3% (n=72) vs 27.3% (n=77) placebo @ 24wk100 mg q8w
responder rate · % of participants
NCT03162796 · Phase 3
show 17 more results
47.9% (n=73) vs 27.3% (n=77) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
18.1% (n=72) vs 22.1% (n=77) placebo @ 4wk100 mg q8w
NCT03162796 · Phase 3
27.4% (n=73) vs 22.1% (n=77) placebo @ 4wk100 mg q4w
NCT03162796 · Phase 3
30.6% (n=72) vs 23.4% (n=77) placebo @ 8wk100 mg q8w
NCT03162796 · Phase 3
30.1% (n=73) vs 23.4% (n=77) placebo @ 8wk100 mg q4w
NCT03162796 · Phase 3
34.7% (n=72) vs 37.7% (n=77) placebo @ 16wk100 mg q8w
NCT03162796 · Phase 3
45.2% (n=73) vs 37.7% (n=77) placebo @ 16wk100 mg q4w
NCT03162796 · Phase 3
40.3% (n=72) vs 27.3% (n=77) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
47.9% (n=73) vs 27.3% (n=77) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
40.8% (n=71) vs 31% (n=71) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
49.3% (n=71) vs 31% (n=71) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
52.9% (n=71) vs 49.3% (n=71) placebo @ 36wk100 mg q8w
NCT03162796 · Phase 3
58% (n=71) vs 49.3% (n=71) placebo @ 36wk100 mg q4w
NCT03162796 · Phase 3
46.4% (n=71) vs 58.2% (n=71) placebo @ 44wk100 mg q8w
NCT03162796 · Phase 3
71.8% (n=71) vs 58.2% (n=71) placebo @ 44wk100 mg q4w
NCT03162796 · Phase 3
56.3% (n=71) vs 69.8% (n=71) placebo @ 52wk100 mg q8w
NCT03162796 · Phase 3
62.9% (n=71) vs 69.8% (n=71) placebo @ 52wk100 mg q4w
NCT03162796 · Phase 3
Leeds Enthesitis Index -1.35 vs -1.01 placebo score @ 24wk100 mg q8w
absolute change · score
NCT03162796 · Phase 3
show 9 more results
-1.75 vs -1.01 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-1.2 vs -1 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
-1.8 vs -1 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-1.3 vs -1.4 placebo score @ 36wk100 mg q8w
NCT03162796 · Phase 3
-2 vs -1.4 placebo score @ 36wk100 mg q4w
NCT03162796 · Phase 3
-1.6 vs -1.6 placebo score @ 44wk100 mg q8w
NCT03162796 · Phase 3
-2.4 vs -1.6 placebo score @ 44wk100 mg q4w
NCT03162796 · Phase 3
-1.8 vs -1.9 placebo score @ 52wk100 mg q8w
NCT03162796 · Phase 3
-2 vs -1.9 placebo score @ 52wk100 mg q4w
NCT03162796 · Phase 3
Dactylitis Resolution 65.3% (n=49) vs 49.1% (n=55) placebo @ 24wk100 mg q8w
responder rate · % of participants
NCT03162796 · Phase 3
show 17 more results
63.2% (n=38) vs 49.1% (n=55) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
34.7% (n=49) vs 41.8% (n=55) placebo @ 4wk100 mg q8w
NCT03162796 · Phase 3
31.6% (n=38) vs 41.8% (n=55) placebo @ 4wk100 mg q4w
NCT03162796 · Phase 3
40.8% (n=49) vs 41.8% (n=55) placebo @ 8wk100 mg q8w
NCT03162796 · Phase 3
44.7% (n=38) vs 41.8% (n=55) placebo @ 8wk100 mg q4w
NCT03162796 · Phase 3
59.2% (n=49) vs 43.6% (n=55) placebo @ 16wk100 mg q8w
NCT03162796 · Phase 3
57.9% (n=38) vs 43.6% (n=55) placebo @ 16wk100 mg q4w
NCT03162796 · Phase 3
65.3% (n=49) vs 49.1% (n=55) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
63.2% (n=38) vs 49.1% (n=55) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
67.3% (n=49) vs 61.7% (n=47) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
64.9% (n=37) vs 61.7% (n=47) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
67.4% (n=49) vs 79.5% (n=47) placebo @ 36wk100 mg q8w
NCT03162796 · Phase 3
82.9% (n=37) vs 79.5% (n=47) placebo @ 36wk100 mg q4w
NCT03162796 · Phase 3
76.1% (n=49) vs 84.8% (n=47) placebo @ 44wk100 mg q8w
NCT03162796 · Phase 3
83.8% (n=37) vs 84.8% (n=47) placebo @ 44wk100 mg q4w
NCT03162796 · Phase 3
79.5% (n=49) vs 81.4% (n=47) placebo @ 52wk100 mg q8w
NCT03162796 · Phase 3
78.4% (n=37) vs 81.4% (n=47) placebo @ 52wk100 mg q4w
NCT03162796 · Phase 3
Dactylitis -6.11 vs -4.3 placebo score @ 24wk100 mg q8w
absolute change · score
NCT03162796 · Phase 3
show 17 more results
-5.82 vs -4.3 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-2.24 vs -2.77 placebo score @ 4wk100 mg q8w
NCT03162796 · Phase 3
-2.63 vs -2.77 placebo score @ 4wk100 mg q4w
NCT03162796 · Phase 3
-4 vs -2.92 placebo score @ 8wk100 mg q8w
NCT03162796 · Phase 3
-3.92 vs -2.92 placebo score @ 8wk100 mg q4w
NCT03162796 · Phase 3
-6 vs -4.03 placebo score @ 16wk100 mg q8w
NCT03162796 · Phase 3
-6.29 vs -4.03 placebo score @ 16wk100 mg q4w
NCT03162796 · Phase 3
-6.11 vs -4.3 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
-5.82 vs -4.3 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-6.2 vs -4 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
-6.6 vs -4 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-6.4 vs -6 placebo score @ 36wk100 mg q8w
NCT03162796 · Phase 3
-7.7 vs -6 placebo score @ 36wk100 mg q4w
NCT03162796 · Phase 3
-7.2 vs -5.3 placebo score @ 44wk100 mg q8w
NCT03162796 · Phase 3
-7.5 vs -5.3 placebo score @ 44wk100 mg q4w
NCT03162796 · Phase 3
-7.8 vs -5.7 placebo score @ 52wk100 mg q8w
NCT03162796 · Phase 3
-7.6 vs -5.7 placebo score @ 52wk100 mg q4w
NCT03162796 · Phase 3
HAQ-DI 26.8% (n=112) vs 20% (n=110) placebo @ 4wk100 mg q8w
responder rate · % of participants
NCT03162796 · Phase 3
show 27 more results
30.9% (n=110) vs 20% (n=110) placebo @ 4wk100 mg q4w
NCT03162796 · Phase 3
40.2% (n=112) vs 25.5% (n=110) placebo @ 8wk100 mg q8w
NCT03162796 · Phase 3
38.2% (n=110) vs 25.5% (n=110) placebo @ 8wk100 mg q4w
NCT03162796 · Phase 3
45.5% (n=112) vs 27.3% (n=110) placebo @ 12wk100 mg q8w
NCT03162796 · Phase 3
51.8% (n=110) vs 27.3% (n=110) placebo @ 12wk100 mg q4w
NCT03162796 · Phase 3
46.4% (n=112) vs 30.9% (n=110) placebo @ 16wk100 mg q8w
NCT03162796 · Phase 3
57.3% (n=110) vs 30.9% (n=110) placebo @ 16wk100 mg q4w
NCT03162796 · Phase 3
50.9% (n=112) vs 28.2% (n=110) placebo @ 20wk100 mg q8w
NCT03162796 · Phase 3
56.4% (n=110) vs 28.2% (n=110) placebo @ 20wk100 mg q4w
NCT03162796 · Phase 3
50.9% (n=112) vs 29.1% (n=110) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
57.3% (n=110) vs 29.1% (n=110) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
53.2% (n=109) vs 36% (n=100) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
57.8% (n=109) vs 36% (n=100) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
61.5% (n=109) vs 40.2% (n=100) placebo @ 28wk100 mg q8w
NCT03162796 · Phase 3
61.5% (n=109) vs 40.2% (n=100) placebo @ 28wk100 mg q4w
NCT03162796 · Phase 3
60.4% (n=109) vs 41.7% (n=100) placebo @ 36wk100 mg q8w
NCT03162796 · Phase 3
61.9% (n=109) vs 41.7% (n=100) placebo @ 36wk100 mg q4w
NCT03162796 · Phase 3
58.7% (n=109) vs 50% (n=100) placebo @ 44wk100 mg q8w
NCT03162796 · Phase 3
62.4% (n=109) vs 50% (n=100) placebo @ 44wk100 mg q4w
NCT03162796 · Phase 3
57.4% (n=109) vs 54.3% (n=100) placebo @ 52wk100 mg q8w
NCT03162796 · Phase 3
68.5% (n=109) vs 54.3% (n=100) placebo @ 52wk100 mg q4w
NCT03162796 · Phase 3
29% (n=100) vs 12.2% (n=49) placebo @ 4wk
NCT02319759 · Phase 2 · registry result, not featured evidence
43% (n=100) vs 26.5% (n=49) placebo @ 8wk
NCT02319759 · Phase 2 · registry result, not featured evidence
47% (n=100) vs 22.4% (n=49) placebo @ 12wk
NCT02319759 · Phase 2 · registry result, not featured evidence
50% (n=100) vs 20.4% (n=49) placebo @ 16wk
NCT02319759 · Phase 2 · registry result, not featured evidence
48% (n=100) vs 22.4% (n=49) placebo @ 20wk
NCT02319759 · Phase 2 · registry result, not featured evidence
51% (n=100) vs 28.6% (n=49) placebo @ 24wk
NCT02319759 · Phase 2 · registry result, not featured evidence
DAS28 (CRP 33.1% (n=127) vs 27% (n=126) placebo @ 4wk100 mg q8w
responder rate · % of participants
NCT03162796 · Phase 3
show 21 more results
40.6% (n=128) vs 27% (n=126) placebo @ 4wk100 mg q4w
NCT03162796 · Phase 3
59.1% (n=127) vs 35.7% (n=126) placebo @ 8wk100 mg q8w
NCT03162796 · Phase 3
54.7% (n=128) vs 35.7% (n=126) placebo @ 8wk100 mg q4w
NCT03162796 · Phase 3
67.7% (n=127) vs 41.3% (n=126) placebo @ 12wk100 mg q8w
NCT03162796 · Phase 3
74.2% (n=128) vs 41.3% (n=126) placebo @ 12wk100 mg q4w
NCT03162796 · Phase 3
65.4% (n=127) vs 44.4% (n=126) placebo @ 16wk100 mg q8w
NCT03162796 · Phase 3
73.4% (n=128) vs 44.4% (n=126) placebo @ 16wk100 mg q4w
NCT03162796 · Phase 3
66.1% (n=127) vs 46% (n=126) placebo @ 20wk100 mg q8w
NCT03162796 · Phase 3
75% (n=128) vs 46% (n=126) placebo @ 20wk100 mg q4w
NCT03162796 · Phase 3
70.9% (n=127) vs 44.4% (n=126) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
76.6% (n=128) vs 44.4% (n=126) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
74.6% (n=123) vs 51.8% (n=114) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
78.4% (n=125) vs 51.8% (n=114) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
83.3% (n=123) vs 73.6% (n=114) placebo @ 28wk100 mg q8w
NCT03162796 · Phase 3
83.9% (n=125) vs 73.6% (n=114) placebo @ 28wk100 mg q4w
NCT03162796 · Phase 3
89% (n=123) vs 76.4% (n=114) placebo @ 36wk100 mg q8w
NCT03162796 · Phase 3
86.8% (n=125) vs 76.4% (n=114) placebo @ 36wk100 mg q4w
NCT03162796 · Phase 3
86.8% (n=123) vs 80% (n=114) placebo @ 44wk100 mg q8w
NCT03162796 · Phase 3
89.5% (n=125) vs 80% (n=114) placebo @ 44wk100 mg q4w
NCT03162796 · Phase 3
88.4% (n=123) vs 86.4% (n=114) placebo @ 52wk100 mg q8w
NCT03162796 · Phase 3
87.8% (n=125) vs 86.4% (n=114) placebo @ 52wk100 mg q4w
NCT03162796 · Phase 3
DAS28 (CRP) Remission 7.9% (n=127) vs 3.2% (n=126) placebo @ 4wk100 mg q8w
responder rate · % of participants
NCT03162796 · Phase 3
show 21 more results
7.8% (n=128) vs 3.2% (n=126) placebo @ 4wk100 mg q4w
NCT03162796 · Phase 3
11% (n=127) vs 7.9% (n=126) placebo @ 8wk100 mg q8w
NCT03162796 · Phase 3
11.7% (n=128) vs 7.9% (n=126) placebo @ 8wk100 mg q4w
NCT03162796 · Phase 3
22% (n=127) vs 9.5% (n=126) placebo @ 12wk100 mg q8w
NCT03162796 · Phase 3
21.9% (n=128) vs 9.5% (n=126) placebo @ 12wk100 mg q4w
NCT03162796 · Phase 3
19.7% (n=127) vs 7.9% (n=126) placebo @ 16wk100 mg q8w
NCT03162796 · Phase 3
25% (n=128) vs 7.9% (n=126) placebo @ 16wk100 mg q4w
NCT03162796 · Phase 3
25.2% (n=127) vs 17.5% (n=126) placebo @ 20wk100 mg q8w
NCT03162796 · Phase 3
36.7% (n=128) vs 17.5% (n=126) placebo @ 20wk100 mg q4w
NCT03162796 · Phase 3
23.6% (n=127) vs 12.7% (n=126) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
35.9% (n=128) vs 12.7% (n=126) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
24.6% (n=123) vs 14.9% (n=114) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
36.8% (n=125) vs 14.9% (n=114) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
37.5% (n=123) vs 26.4% (n=114) placebo @ 28wk100 mg q8w
NCT03162796 · Phase 3
38.7% (n=125) vs 26.4% (n=114) placebo @ 28wk100 mg q4w
NCT03162796 · Phase 3
40.7% (n=123) vs 39.1% (n=114) placebo @ 36wk100 mg q8w
NCT03162796 · Phase 3
40.5% (n=125) vs 39.1% (n=114) placebo @ 36wk100 mg q4w
NCT03162796 · Phase 3
45.6% (n=123) vs 38.1% (n=114) placebo @ 44wk100 mg q8w
NCT03162796 · Phase 3
51.6% (n=125) vs 38.1% (n=114) placebo @ 44wk100 mg q4w
NCT03162796 · Phase 3
43.8% (n=123) vs 37.9% (n=114) placebo @ 52wk100 mg q8w
NCT03162796 · Phase 3
56.1% (n=125) vs 37.9% (n=114) placebo @ 52wk100 mg q4w
NCT03162796 · Phase 3
PsARC 29.1% (n=127) vs 20.6% (n=126) placebo @ 4wk100 mg q8w
responder rate · % of participants
NCT03162796 · Phase 3
show 21 more results
33.6% (n=128) vs 20.6% (n=126) placebo @ 4wk100 mg q4w
NCT03162796 · Phase 3
56.7% (n=127) vs 32.5% (n=126) placebo @ 8wk100 mg q8w
NCT03162796 · Phase 3
48.4% (n=128) vs 32.5% (n=126) placebo @ 8wk100 mg q4w
NCT03162796 · Phase 3
58.3% (n=127) vs 41.3% (n=126) placebo @ 12wk100 mg q8w
NCT03162796 · Phase 3
66.4% (n=128) vs 41.3% (n=126) placebo @ 12wk100 mg q4w
NCT03162796 · Phase 3
64.6% (n=127) vs 36.5% (n=126) placebo @ 16wk100 mg q8w
NCT03162796 · Phase 3
68% (n=128) vs 36.5% (n=126) placebo @ 16wk100 mg q4w
NCT03162796 · Phase 3
66.1% (n=127) vs 41.3% (n=126) placebo @ 20wk100 mg q8w
NCT03162796 · Phase 3
75.8% (n=128) vs 41.3% (n=126) placebo @ 20wk100 mg q4w
NCT03162796 · Phase 3
59.8% (n=127) vs 31% (n=126) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
72.7% (n=128) vs 31% (n=126) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
63.1% (n=123) vs 37.2% (n=114) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
74.4% (n=125) vs 37.2% (n=114) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
78.7% (n=123) vs 64.9% (n=114) placebo @ 28wk100 mg q8w
NCT03162796 · Phase 3
82.3% (n=125) vs 64.9% (n=114) placebo @ 28wk100 mg q4w
NCT03162796 · Phase 3
80.5% (n=123) vs 68.8% (n=114) placebo @ 36wk100 mg q8w
NCT03162796 · Phase 3
80% (n=125) vs 68.8% (n=114) placebo @ 36wk100 mg q4w
NCT03162796 · Phase 3
81.9% (n=123) vs 73.8% (n=114) placebo @ 44wk100 mg q8w
NCT03162796 · Phase 3
80% (n=125) vs 73.8% (n=114) placebo @ 44wk100 mg q4w
NCT03162796 · Phase 3
83.8% (n=123) vs 73.8% (n=114) placebo @ 52wk100 mg q8w
NCT03162796 · Phase 3
83.9% (n=125) vs 73.8% (n=114) placebo @ 52wk100 mg q4w
NCT03162796 · Phase 3
Enthesitis -0.45 vs -0.37 placebo score @ 4wk100 mg q8w
absolute change · score
NCT03162796 · Phase 3
show 7 more results
-0.96 vs -0.37 placebo score @ 4wk100 mg q4w
NCT03162796 · Phase 3
-0.83 vs -0.65 placebo score @ 8wk100 mg q8w
NCT03162796 · Phase 3
-1.11 vs -0.65 placebo score @ 8wk100 mg q4w
NCT03162796 · Phase 3
-1 vs -0.99 placebo score @ 16wk100 mg q8w
NCT03162796 · Phase 3
-1.51 vs -0.99 placebo score @ 16wk100 mg q4w
NCT03162796 · Phase 3
-1.35 vs -1.01 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
-1.75 vs -1.01 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
PASDAS -1.315 vs -0.759 placebo score @ 8wk100 mg q8w
absolute change · score
NCT03162796 · Phase 3
show 11 more results
-1.428 vs -0.759 placebo score @ 8wk100 mg q4w
NCT03162796 · Phase 3
-1.779 vs -0.98 placebo score @ 16wk100 mg q8w
NCT03162796 · Phase 3
-2.083 vs -0.98 placebo score @ 16wk100 mg q4w
NCT03162796 · Phase 3
-2.124 vs -0.959 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
-2.407 vs -0.959 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-2.246 vs -1.14 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
-2.413 vs -1.14 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-2.897 vs -2.748 placebo score @ 52wk100 mg q8w
NCT03162796 · Phase 3
-3.026 vs -2.748 placebo score @ 52wk100 mg q4w
NCT03162796 · Phase 3
-2.24 vs -0.45 placebo score @ 16wk
NCT02319759 · Phase 2 · registry result, not featured evidence
-2.5 vs -0.49 placebo score @ 24wk
NCT02319759 · Phase 2 · registry result, not featured evidence

+ 78 further endpoints in the CSV export.

risankizumab

Tender Joint Count -9.6 vs -7.9 placebo tender joints @ 16wk150 mg weeks 0, 4, and 16
absolute change · tender joints
NCT02719171 · Phase 2 · registry result, not featured evidence
show 5 more results
-10.4 vs -7.9 placebo tender joints @ 16wk150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-9.9 vs -7.9 placebo tender joints @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-7.8 vs -7.9 placebo tender joints @ 16wk150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
-8.6 vs -7.9 placebo tender joints @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
-10.8 vs -7.9 placebo tender joints @ 16wk75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
Swollen Joint Count -7.8 vs -7.1 placebo swollen joints @ 16wk150 mg weeks 0, 4, and 16
absolute change · swollen joints
NCT02719171 · Phase 2 · registry result, not featured evidence
show 5 more results
-8.3 vs -7.1 placebo swollen joints @ 16wk150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-8.3 vs -7.1 placebo swollen joints @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-6.8 vs -7.1 placebo swollen joints @ 16wk150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
-7.3 vs -7.1 placebo swollen joints @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
-7.8 vs -7.1 placebo swollen joints @ 16wk75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
Dactylitis -1.9 vs -2.6 placebo fingers and toes with dactylitis @ 16wk150 mg weeks 0, 4, and 16
absolute change · fingers and toes with dactylitis
NCT02719171 · Phase 2 · registry result, not featured evidence
show 5 more results
-2.9 vs -2.6 placebo fingers and toes with dactylitis @ 16wk150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-2.4 vs -2.6 placebo fingers and toes with dactylitis @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-1.1 vs -2.6 placebo fingers and toes with dactylitis @ 16wk150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
-1.5 vs -2.6 placebo fingers and toes with dactylitis @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
-3.5 vs -2.6 placebo fingers and toes with dactylitis @ 16wk75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
mNAPSI -5.8 vs -5.2 placebo score @ 16wk150 mg weeks 0, 4, and 16
absolute change · score
NCT02719171 · Phase 2 · registry result, not featured evidence
show 5 more results
-10.7 vs -5.2 placebo score @ 16wk150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-8.1 vs -5.2 placebo score @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-6.7 vs -5.2 placebo score @ 16wk150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
-5.5 vs -5.2 placebo score @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
-6.8 vs -5.2 placebo score @ 16wk75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: guselkumab's landscape · risankizumab's landscape